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Colorectal cancer (CRC) is the second most common cause of cancer related deaths in the United 
States, mainly due to metastasis to the distant organ sites.  However, the molecular basis of CRC 
metastasis is poorly understood.  Therefore, identification and characterization of novel potential 
anti-cancer therapeutic targets CRC is of urgent need.  Utilizing a 2D-DIGE proteomics approach 
ezrin was identified as a protein that is differentially expressed between primary colon tumors 
xenografts, orthotopically implanted in athymic nude mice, and corresponding and liver 
metastatic deposits.  Ezrin, a cytoskeletal protein belonging to the ezrin–radixin–moesin (ERM) 
family plays important roles in cell motility, invasion and metastasis. However, its function in 
CRC is not well characterized. Increased phosphorylation of ezrin at the T567 site (termed here as 
p-ezrin T567) was observed in liver metastasis as compared to the primary tumors in both 
orthotopic xenograft mouse models and human CRC patient specimens. Inhibition of ezrin 
activation by siRNA, shRNA, pharmacological inhibitor or an ezrin phospho-deficient T567A 
mutant significantly increased cell death associated with downregulation of inhibitors of 
apoptosis (IAP) proteins, XIAP and survivin which have been linked to aberrant cell survival and 
metastasis. In addition inhibition of the IGF1R signaling pathway by the humanized recombinant 
IGF1R monoclonal antibody MK-0646 in subcutaneous xenografts resulted in the inhibition of p-
ezrin T567. Furthermore, TGFβ/Smad3 signaling inhibits ezrin phosphorylation at T567. These 
results suggest that ezrin is a downstream effector of the   IGF1R and TGFβ signaling pathways. 
          Ezrin is a known cAMP dependent A-kinase Anchoring Protein (AKAP). We demonstrate 
that the knockdown or inhibition of ezrin activates PKA in a cAMP-independent manner leading 
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and leads to decreased expression of XIAP and survivin and CRC cell death. Interestingly, ezrin 
activation by hyperphosphorylation at T567 also activates PKA, but in cAMP-dependent manner 
leading to CRC cell survival and upregulation of XIAP and survivin. These results were further 
confirmed with ezrin T567 phospho-mimetic (T567D) and phospho-deficient (T567A) mutants 
which demonstrated PKA activation by cAMP-dependent and independent mechanisms 
respectively leading to different CRC cell fates. Hence, there are two opposing pathways 
mediated by ezrin in which PKA is activated but results in different cell fates. 
          Therefore, ezrin might be a novel target that could be utilized for the development of new 
therapeutic strategies. Further understanding of the mechanisms by which PKA is activated and 
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1.    Introduction 
1.1.    Cancer initiation and development 
Cancer is the second leading cause of death in the United States. Under normal conditions when 
the cells grow old they would die and new cells replace them to maintain homeostasis. In cancer, 
however, this orderly process is altered. Old or damaged cells survive by evading the cell death 
mechanism and new cells develop even when not needed leading to uncontrolled cell growth, as 
shown in Figure 1.1 [1, 2]. Cancers are classified either by the tissue of origin (histological type) 
or by primary site. According to their tissue of origin cancers are named as carcinoma, sarcoma, 
leukemia, lymphoma, myeloma and CNS tumors, many of which form solid tumors [3]. 
According to National Cancer Institute (NCI) cancer statistics 2017 an estimated 1,688,780 new 
cancer cases and 600,920 cancer deaths are projected to occur in the United States. Of these 
cancers, lung and bronchus cancer, prostate cancer, colorectal cancer and breast cancer are the 
most common causes of cancer related death and account for approximately 46% of the cases 
(SEER 2007-2013). Almost all cancers are malignant in nature, which means they can invade 
nearby tissues or travel to the distant organs that are far from the original tumor sites in the body 
either through the lymphatics or bloodstream [4, 5]. 
             Metastatic disease is responsible for more than 90% of cancer related death, mainly due 
to the resistance to conventional therapies [1, 4, 6]. Understanding the molecular and cellular 
natures of metastatic progression is critical for the development of therapies against cancer. 
Metastatic progression involves an orderly sequence of a tightly regulated multistage process 
consisting of local invasion of the malignant cells, intravasation into lymph nodes and blood 
vessels, survival in the circulation by neovascularization, dispersal through the circulation, 
extravasation from the blood vessels and finally colonization in the target organs [5-10]. These 
events are facilitated by different classes of metastatic genes that mediate metastatic initiation, 
progression and colonization functions [5, 11]. 
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1.2.    Overview of colorectal cancer 
Colorectal cancer (CRC) is one such cancer where metastasis to the distant organs is the main 
cause of cancer related death [5, 10, 11]. CRC is the fourth most common and second leading 
cause of cancer death in United States. According to the NCI cancer statistics report for 2017 
there will be 135,430 estimated new cases of CRC with an estimated 50,260 death this year. CRC 
initially develops as an adenomatous benign polyp which gradually progresses to carcinoma in 
situ (CIS) and invasive carcinoma. According to the TNM classification, there are four stages 
(stage I-IV). In stages I and II, the tumor is localized to the primary site and has 89.9% five-year 
survival rate; for stage III where cancer spreads to regional organs, and stage IV- where cancer 
metastasizes to distant organs such as liver and lungs the five years’ survival rate is reduced to 
71.3% and 13.9% respectively (SEER 2007-2013). Therefore, CRC when diagnosed early can be 
cured by surgical resection, however, when metastasis has spread to distant organs sites like liver 
and/or lungs, the survival rate of patients is drastically reduced. Regardless of the significant 
improvements in early diagnosis and treatment of CRC, metastasis and recurrence of the disease 
due to resistance to conventional therapies remain the main cause of cancer related death [6]. 
Genetic alterations required for CRC metastasis are mainly acquired during the progression to 
invasive stage at the primary site [5, 11-16]. Colorectal cancer progression has three main events: 
loss of function mutation of tumor suppressors, gain of function mutation of oncogenes and 
alterations in DNA methylation patterns [11]. As shown in the Vogelgram model (Figure 1.2), 
loss of adenomatous polyposis coli (APC) is associated with adenoma formation which is the 
initial step in tumorigenesis; larger adenomas and early carcinomas acquire mutations in the small 
GTPase KRAS, followed by loss of chromosome 18q with SMAD4, which is downstream of 
transforming growth factor beta (TGFβ), and mutations in TP53 in frank carcinoma [11, 17]. 
TGFβ signaling is altered in approximately 30% of CRC patients and is mainly due to mutation in 
TGFβ receptor type II (RII) [18, 19]. Moreover, studies have shown that IGF1R signaling also 
participates in the progression of CRC [20, 21]. At present there are few therapies available for 
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CRC metastasis. Therefore, identification of potential novel biomarkers involved in these 
processes that are metastases specific would be an important milestone in addressing the urgent 
need in the treatment of disseminated diseases in CRC to improve patient survival. This 
dissertation studied the IGF1R and TGFβ signaling pathways and the downstream molecules 
involved in these two pathways. 
1.3.    IGF1R signaling and cancer regulation 
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase receptor [22, 23]. Upon 
ligand binding, IGF1R is activated through autophosporylation in the C- terminus kinase domain 
of the receptor, and subsequently phosphorylates insulin receptor substrate (IRS) [22, 23]. 
Recruitment of these molecules leads to the activation of downstream signaling via the 
phosphatidylinositol-3-kinase (PI3K)-Akt and RAS/RAF/mitogen-activated protein kinase 
(MAPK) pathways [22, 24, 25]. The downstream PI3K/Akt pathway performs a variety of 
functions, such as releasing the anti-apoptotic protein Bcl-2 from Bad, activating protein 
synthesis through mTOR, and promoting glucose metabolism by inhibiting GSK-3β [22, 26]. In 
parallel, IGF1R signaling also promotes cell proliferation via the Ras/MAPK pathway (Figure 
1.3) [20, 22]. 
       The insulin-like growth factor (IGF) signaling axis is critical to the growth, development, 
and maintenance of many tissues within the human body. It is particularly important during 
neonatal and pubertal growth, and essentially carries out its effects by simulating cell 
proliferation and interrupting programmed cell death [21, 22]. Recently IGF1R signaling has been 
shown to play a role in increasing life span [22].  IGF1R is overexpressed by many tumors, and 
mediates proliferation and apoptosis protection [22], and this aberrant expression is preceded by 
an earlier molecular event, such as loss of function of tumor suppressor genes, or gain of function 
mutations in p53 [22, 27, 28].  The IGF1R pathway is overexpressed in more than 30% of 
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patients with CRC [29], therefore identification of molecular targets in the IGF1R signaling 
pathway will provide insight into the potential therapeutic targets for this disease. 
1.4.    TGFβ signaling and its role in cancer 
TGFβ belongs to the TGFβ superfamily of cytokines, which also includes bone morphogenetic 
proteins (BMP), activins, inhibins and others members [30]. TGFβ and the downstream pathway 
components regulate diverse cellular functions such as growth, adhesion, migration, apoptosis,  
differentiation, angiogenesis, immune surveillance and survival [31, 32], and are well conserved 
during evolution [32]. 
TGFβ has three isoforms (TGFβ1, TGFβ2, and TGFβ3) with about 70-80% sequence 
homology, and TGFβ1, commonly known as TGFβ, is the most ubiquitously expressed among 
them [31]. TGFβ1 ligand binding to the TGFβ receptor type II (TGFβRII) causes auto 
phosphorylation on the TGFβ receptor, which in turn leads to the recruitment and 
transphosphorylation of the TGFβ receptor type I (TGFβRI). This leads to the activation of this 
serine/threonine kinase receptor, which can now bind to and phosphorylate Receptor- Smads 
family (R-Smads) that complex with Co-Smads (Smad4) and translocate to the nucleus, thereby 
regulating the TGFβ transcriptional response [33, 34]. Thus TGFβ signaling is a two-step 
mechanism: TGFβ receptor complex mediated activation of Smad and the Smad complex-
mediated transcription of genes, as shown in Figure 1.4 [35]. 
             TGFβ is one of the genes that have loss of function mutations in early stages of CRC 
[11]. In fact, the overall incidence of TGFBRII mutations is close to 30% in colorectal cancer and 
is the most common mechanism identified so far for TGFβ signaling alteration [36]. Previous 
studies have also shown that TGFβ acts as an autocrine regulator that negatively regulates 
proliferation in several different epithelial cell lines including colon cells. Therefore, loss of this 
autocrine activity and/or loss of responsiveness to exogenous TGFβ by receptor mutation may 
provide epithelial cells with growth advantage, leading to malignant progression in early disease 
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[31]. A recent study in our laboratory has shown that TGFβ signaling regulates CRC cell death in 
a PKA/AKAP149-dependent manner and cAMP-independent manner through downregulation of 
XIAP expression in vitro [16]. This dissertation focused on this mechanism of CRC cell death. 
1.5.    Protein Kinase A (PKA) 
Protein kinase A (PKA) is a serine/threonine protein kinase that belongs to the AGC kinase 
(cAMP-dependent protein kinase A, cGMP-dependent protein kinase G, and phospholipid 
dependent protein kinase C) family [37]. PKA is a holoenzyme that consists of two regulatory (R) 
and two catalytic (C) subunits [38]. In its inactive state each C subunit remains bound to one R 
subunit. Binding of two cAMP molecules to each of the R subunit results in a conformational 
change in the R subunits, thereby lowering their affinity towards the C subunits [38, 39]. This 
results in the release and activation of the C subunit, which then phosphorylate serine and 
threonine residues on nearby specific substrate proteins in specific subcellular compartments, as 
shown in Figure 1.5 [39]. In the nucleus, PKA phosphorylates the cAMP response element 
binding (CREB) family and induces gene expression [40]. 
             The R subunits are highly dynamic multi-domain proteins that interact with a variety of 
proteins in addition to serving as major receptors for cAMP [41]. Although different subunit 
isoforms (RIα, RIβ, RIIα, and RIIβ) have different affinities for cAMP, all of them retain a 
similar general architectural organization. All the R subunits consist of three major domains: an 
N-terminal dimerization and docking (D/D) domain which is the docking site for the A kinase-
anchoring protein (AKAP) and two cAMP binding domains (CBD), referred to here as domains 
A and B. The D/D domain is connected to the CBD domain by a linker region [42]. The D/D 
domains of two R subunit monomers form a four-helix-bundle, thereby achieving the 
dimerization of R subunits and providing the docking site for AKAP [43]. 
Depending on different subunit composition and affinity for cAMP, PKA is classified as 
PKA type I (PKAI) or type II (PKAII). These molecules are activated at either low or high local 
concentrations of cAMP in the cell [44]. The AKAP proteins play an important role in targeting 
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of PKA types I and II to different subcellular compartments. Type I PKA is mostly located in the 
cytoplasm and the majority of type II PKA is anchored to subcellular structures [45-47]. PKA 
lacks the canonical protein-protein or protein-lipid interaction domains present in many other 
AGC kinases that control their localization. This explains the important role AKAP proteins play 
in controlling the localization of PKA [37]. The different properties of the components of various 
PKA holoenzymes, with respect to cAMP sensitivity and interaction with AKAP, enhance the 
specificity of cAMP/PKA signaling [44]. It has also been shown that PKA can be activated 
independently of cAMP [16].              
Several studies have shown that cAMP/PKA signaling is deregulated in many cancers 
and has been linked to aberrant cell cycle regulation and development of cancer [48]. 
Involvement of PKA in neoplastic transformation and tumor growth has been seen in endocrine 
and thyroid tumors [49]. PKA has been shown to be involved in the migration of breast 
carcinoma cells [48] and ovarian cancer cells [50]. Recently, studies from our laboratory have 
also shown that PKA can be activated with or without cAMP involvement through interaction 
with different AKAP proteins, leading to different cell fates [51]. Therefore, dissecting the 
various proteins involved in this dual PKA activation leading to differential cell fates in CRC 
cells is critical for identifying potential therapeutic targets. 
1.6.    A-kinase anchoring protein (AKAP) 
Scaffolding of numerous kinases and phosphatases by anchoring proteins have been identified 
and understanding that these enzymes phosphorylate different substrate in cells is critical. The 
prototype kinase is PKA (Protein Kinase A), which becomes activated through the binding of the 
second messenger cAMP [41]. PKA is involved in numerous signaling cascades in cells, 
therefore understanding the mechanism of PKA activation at the right time and right place is 
important [41]. A-kinase anchoring protein (AKAP) interacts with PKA and participates in the 
compartmentalization of PKA in different sub-cellular localization [39, 52] 
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             AKAP was first identified as protein that co-purified with PKA holoenzyme. Since then 
more than 50 AKAP proteins have been identified so far through a variety of techniques such as 
gel overlay, interaction cloning, yeast two-hybrid and proteomic approaches [52]. Microtubule-
associated protein-2(MAP2), the first AKAP to be characterized, was co-purified with RII subunit 
of PKA from brain extract [47]. The characteristic property common to all AKAP proteins is the 
presence of a PKA-binding domain, also named RII-binding domain (RIIBD) because most 
AKAPs mainly anchor the RII subunits [52]. The RIIBD consists of an amphipathic α-helix of 14 
to 18 amino acids and the hydrophobic face of this helix binds to a hydrophobic groove formed 
by the four-helix bundle of a PKA R subunit D/D domain dimer (Figure 1.6) [52].                        
             With the increase in the number of AKAP binding partners, it is apparent that AKAP has 
the potential to organize different subsets of enzyme partners in a context specific manner. 
AKAP-PKA binding specificity is delivered by the specific large motif that directs AKAP to 
different subcellular compartments, such as protein-protein interaction to structural element or 
through protein lipid interaction to membrane [53]. For example, AKAP 79 has non-contiguous 
basic regions that facilitate association with acid phosphatase in the plasma membrane [54]. 
Furthermore, mAKAP, an anchoring protein structure expressed in cardiac muscles, is targeted to 
the membrane of the cardiomyocyte through a 3 spectrin-like lipid structure [55]. Wave proteins 
(WAVE1, Wave2 and Wave3) coordinate different signaling complexes in a tissue-specific as 
well as compartment-specific manner [56]. Studies have shown that the targeting of different 
AKAPs to different compartments can be regulated through alternative splicing of AKAP genes 
[56]. DAKAP-1, a dual specificity AKAP, has distinct targeting sequences that are located within 
the amino terminus that help in the localization of spice variants to either mitochondria or 
endoplasmic reticulum [56]. Consequently, AKAPs tether PKA to most organelles (e.g. the 
plasma membrane, the cytoskeleton, mitochondria, the Golgi apparatus, the nucleus or vesicular 
structures) in close proximity of its substrates. The most significant biological property of AKAP 
is their ability to co-localize PKA with other signaling enzymes such as protein phosphatases, 
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protein kinases such as Akt/protein kinase B (PKB), protein kinase C (PKC), protein kinase D, 
protein kinase N [47], extracellular-signal regulated kinase (ERK) 1/2 [57] or glycogen synthase 
kinase-3β (GSK3β), a serine/threonine kinase in the Wnt pathway [58, 59].  These showed that by 
binding to a multiplex of signaling molecules, AKAPs can orchestrate a variety of combination of 
enzymes at specific sub-cellular locations, as shown in Figure 1.7. 
             Although much is known about AKAP molecular regulation of anchored enzyme activity, 
another aspect to discuss is the function of AKAP. AKAP plays a role in diverse physiological 
processes such as cardiac function, hearing, memory, reproduction, development, and in diseases 
such as cancer and diabetes [60]. For example, in cardiac muscle, AKAP-lbc mediated activation 
of PKD leads to cardiac hypertrophy; however, AKAP-lbc targeted PKA signaling prevents Rho-
mediated cardiac hypertrophy, showing that AKAP binding with different substrates can have 
different effector functions [61]. AKAP also plays a role in cancer progression. Gravin 
(AKAP13) suppressed PKC-Raf/ Mek/ ERK signaling, leading to decreased cancer cells’ 
invasiveness. Dysregulation of gravin, in turn leads to increased cancer progression in prostate, 
breast and ovarian cancers [62]. Recently, it has been shown that different AKAPs can activate 
PKA in a context-dependent manner, leading to either cell survival or cell death [16, 51]. In this 
dissertation we discuss the role of different AKAPs in determining CRC cell fates. 
1.7.    Ezrin  
Ezrin belongs to the ezrin-radixin-moesin (ERM) protein family, which share ~ 75% sequence 
homology [63-66]. Ezrin was first characterized as a minor component of intestinal brush border 
microvilli [67]. ERM consists of two binding domains: the highly conserved NH2-terminal 
plasma membrane binding domain, (also called FERM domain) and the COOH- terminal F-actin 
binding domain [65, 68], together with the central α-helical region, as shown in Figure 1.8 [69]. 
ERM binds to membrane proteins either directly or through adaptor proteins such as 
NHERF1/2[70]. CD44/43, ICAM2/3 were also identified as binding partners for ERM protiens 
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on the plasma membrane [71-75]. This coexistence in individual molecule allows ERM proteins 
to function as plasma membrane/actin filament cross-linkers [76]. In native ezrin molecule, the 
FERM and COOH-terminal domains are bound tightly in head to tail fashion, masking several of 
its binding sites, including the F-actin binding domain and in turn regulating ezrin activity [77, 
78]. Ezrin, thus provides a regulated linkage between the plasma membrane and the actin 
cytoskeleton [79]. Ezrin plays important roles in cell motility, invasion and tumor progression 
[80-83] and has been implicated in metastasis of several types of cancer [84-87]. However, its 
function in CRC remains elusive.  
             Phosphorylation of ERM proteins at the C-terminal domain threonine is critical for their 
activation [88, 89]. Previous studies have shown that upon phosphatidylinositol 3,4-bisphosphate 
(PtdIns(4,5)P2) binding and phosphorylation at T567 fixed ezrin in the activated open 
conformation by regulating its transition to active monomers from inactive oligomers by 
unmasking the F-actin binding site through dissociation of the binding of FERM and COOH-
terminal domains (Figure 1.9) [90]. Serine/threonine kinases such as Rho-kinase (ROCK) [76, 91, 
92], protein kinase Cα (PKCα), PKCθ [76, 93], Cdc 42 [94], and G protein-coupled receptor 
kinase 2 (GRK2) [95] have been implicated in being responsible for ezrin phosphorylation at 
T567.  Studies have shown other serine/threonine and tyrosine residues phosphorylation sites of 
ezrin and these sites are linked to specific functions. PKA-mediated phosphorylation of ezrin at 
S66 regulates remodeling of the apical membrane cytoskeleton associated with acid secretion in 
parietal cells [96], while cyclin dependent kinase 5 (Cdk5)-mediated phosphorylation of ezrin 
T235 leads to pRb-induced cell senescence [97]. Upon stimulation by growth factors such as 
EGF, ezrin is phosphorylated on Y353 and has been associated with cell survival during epithelial 
cell differentiation through the PI3K/Akt pathway [81]. Src, a tyrosine kinase also phosphorylates 
ezrin at multiple tyrosine phosphorylation sites such as Y190, Y145 and Y477 [98, 99]. 
             Ezrin is expressed in a variety of tissues, mainly in the apical surface of epithelial cells, 
and plays an important role in maintaining epithelial polarity during normal development [72, 
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100]. Ezrin is the most abundant among the ERM protein and is the only ERM protein expressed 
in the gut. Ezrin has also been implicated in development of gastric parietal cells, which are 
responsible for hydrochloric acid production, and of retinal pigment epithelial cells [100]. 
Homozygous ezrin knockout mice are unable to survive past weaning, and this may be due to 
defects in epithelial organization and villus morphogenesis in the gastrointestinal tract [101]. 
Mouse knockouts for the other ERM proteins have also been generated and all have been found to 
play a major role in membrane organization [102]. Therefore, there may be functional 
redundancy among the ERM proteins as a result of the similarities in their structure.  
             In 1997, Dransfield et al. first isolated and identified ezrin as a cyclic AMP (cAMP)-
dependent A kinase anchoring protein (AKAP) from parietal cells [103]. Ezrin binds to the PKA 
RII subunit through its α- helical domain [103, 104]. Ezrin has also been shown to be a dual-
specific AKAP, anchoring both type I and type II PKA [104]. Ezrin-PKA activation initiates 
NHERF1 phosphorylation to disassemble the ezrin-NHERF1-Npt2a ternary complex, releasing 
Npt2a, and thereby, inhibiting phosphate transport in urinary epithelium [104]. Ezrin has also 
been shown to involve in the regulation of B-cell and T-cell signaling [105, 106].  
             Ezrin is overexpressed in many cancers, such as osteosarcoma, glioblastoma, pancreas 
carcinoma, breast carcinoma, ovarian carcinomas, endometrioid carcinomas, lung 
adenocarcinomas, and primary cutaneous melanomas [80, 83, 107-109]. Studies have also shown 
that ezrin is required for osteosarcoma’s and rhabdomyosarcoma’s metastasis, and there is 
association of increased ezrin expression with advancing histological grade in sarcomas [109]. 
Moreover, increased membranous expression of ezrin is associated with poor overall survival in 
pancreatic cancer [87]. Ezrin is activated through phosphorylation at T567, and activated ezrin at 
T567 is correlated with hepatocellular carcinoma (HCC) [85] and osteosarcoma metastases in 
vivo [84, 110]. However, the role of ezrin in CRC survival has not been fully explored. The work 
in this dissertation demonstrated the role of ezrin-mediated cell survival in CRC. 
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1.8.    Inhibitor of Apoptosis Proteins (IAP)  
Inhibitors of Apoptosis Proteins (IAPs) were first identified in baculoviruses and have been found 
in Drosophila and vertebrates [111, 112]. IAP proteins are characterized by one or more 70-80-
amino acids baculoviral IAP repeats (BIR) domains that coordinate a zinc ion and are critical for 
IAP antiapoptotic properties [112]. The BIR domains are critical for IAP binding with several 
binding partners such as caspases [111]. At present there are seven mammalian IAP proteins. Out 
of these, XIAP, cIAP1, cIAP2 and NAID have three BIR domains that mediate antiapoptotic 
activity [111]. However, survivin, livin and TsIAP have only one BIR domain and mostly 
function in cytokinesis and chromatin segregation with a possible secondary role in apoptosis 
[111]. Together with the BIR domain, IAP family members also possess a caspase recruitment 
domain (CARD) domain and a carboxyl terminal RING zinc finger domain, however not all BIR-
containing IAPs possess these motifs, as shown in Figure 1.10 [111]. XIAP and survivin are 
among the most characterized cell survival IAPs and are discussed in this study.         
1.8.1.    XIAP 
X-linked inhibitor of apoptosis protein (XIAP or BIRC4) is a member of the mammalian IAP 
family of proteins. Of all the IAPs, mammalian XIAP is well characterized and functions as a 
direct inhibitor of caspases [113]. XIAP overexpression inhibits caspases 3, 7and 9 activations 
and apoptosis through both intrinsic and extrinsic apoptotic pathways [113]. XIAP has also been 
independently characterized as a metastatic gene [114].  
   XIAP has three BIR domains (BIR1, BIR2 and BIR3), and a carboxyl terminal RING 
domain which has E3 ubiquitin ligase activity (Figure 1.10) [111]. XIAP directly binds to the 
effector caspases 3 and 7 and initiator caspase 9 through their BIR domains. The linker region 
residues between the BIR1 and BIR2 domain binds to the catalytic pocket of caspases 3 and 7, 
thereby blocking substrate entry and inhibiting these effector caspases [113]. The BIR2 domain 
has a limited role in the mechanism of caspase inhibition since the linker region before the BIR2 
domain has all the inhibitory contact regions. However, the BIR2 domain binds to the IAP 
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binding motif (IBM) at the amino terminal of caspases 3 and 7 subunits following their activation 
[113]. In inactive caspases 3 and 7, the IBM motif remains hidden and is exposed following 
activation through their cleavage. The binding of XIAP BIR2 domain to the IBM motif of the 
activated effector caspases strengthens caspase binding and is critical for XIAP to effectively 
dock onto the effector caspases for their inhibition [113]. The mechanism of XIAP-mediated 
initiator caspase 9 regulation is fundamentally different. Here, the XIAP BIR3 domain binds to 
the IBM motif of caspase 9 and blocks its activity. This is due to XIAP-mediated prevention of 
caspase 9 dimerization, a prerequisite of initiator caspase activity [113]. However, under stress, 
mitochondrial Smac interacts with the BIR3 domain of XIAP in the cytosol, and this interaction 
competes with caspase 9 binding to XIAP. This promotes the release of caspase 9 from 
XIAP/caspase 9 complex, leading to apoptosis initiation [115]. The RING domain with E3 ligase 
activity ubiquitinates target proteins for proteasomal degradation, and this activity of XIAP is 
important for the regulation of apoptosis and contributes to tumor suppression [116]. Studies have 
also shown that mutation of the RING domain stabilizes XIAP and promotes apoptosis resistance 
[116]. 
1.8.2.    Survivin         
Survivin, a 16.5 kDa protein is the smallest member of the mammalian IAP family of proteins 
[117]. It contains a single BIR domain, which is the hallmark of all IAPs, and a carboxyl terminal 
α-helical coiled coil domain, but lacks the RING domain (Figure 1.10) [118, 119]. A single 
survivin gene has three alternatively spliced variants, which are differentially expressed in 
cancers and play a role in cell survival mechanisms [120].  
             Survivin is ubiquitously expressed in both embryonic and fetal development, and in 
proliferating cells of small intestinal and colonic crypts, but it is undetectable in most terminally 
differentiated adult tissues [121, 122]. However, it is differentially expressed in almost all cancers 
and lymphomas [121, 122]. Survivin is linked to multiple pathways of cellular homeostasis and 
its expression is regulated at both transcriptional and post-transcriptional levels [121]. Survivin is 
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expressed in several subcellular compartments, inhibits apoptosis, promotes tumor-associated 
angiogenesis and provides resistance to various anti-cancer drugs [121, 122]. Survivin is a 
cytoprotective molecule that helps in protecting a pool of molecules segregated in mitochondria 
and released in the cytosol. However, it does not directly inhibit caspases but rather interacts with 
other proteins, mostly XIAP [122, 123]. Under stress, survivin is released from the mitochondria 
and associates with XIAP. This interaction increases the stabilization of XIAP against 
degradation, leading to inhibition of caspases and activation of multiple signaling molecules 
downstream. This leads to apoptosis suppression and acceleration of tumor progression in vivo 
[124]. However, this survivin-XIAP interaction is negatively regulated by compartmentalized 
PKA signaling mediating survivin phosphorylation at serine 20 in the cytosol but not in the 
mitochondria [124]. Survivin has also been shown to play a role in sequestration of mitochondrial 
Smac protein in response to apoptotic stimuli, resulting in the inhibition of Smac binding to other 
IAP members and inhibiting apoptosis [125]. Survivin also plays a role in mitosis. It is a member 
of the chromosomal passenger complex (CPC) and is involved in chromosomal segregation 
[126]. Because it is ubiquitously expressed in almost all cancer types and is undetectable in 
normal tissues, survivin has been extensively studied as a novel therapeutic target [122]. 
             Independently of their cell survival functions, both XIAP and survivin have been 
implicated as pro-metastatic genes [114]. In this dissertation, we focused on the cell survival role 
of these two mammalian IAPs, XIAP and survivin, discussed in the following chapters. 
1.9. Scope of the dissertation 
The work in this dissertation focused on the role of ezrin in CRC cell survival regulation. The 
first project (Chapter 2) focused on MK-0646, a novel humanized IGF1R monoclonal antibody, 
and IGF1R small molecule inhibitor OSI-906 in causing cell death in CRC cells through 
downregulation of cell survival IAPs XIAP and survivin. This work demonstrated that MK-0646 
has comparable antitumor effects to OSI-906, and may be a potential novel targeted therapy 
against an IGF1R-dependent subset of human CRC. In the second project (Chapter 3), a 
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proteomic approach was utilized to identify ezrin as one of the proteins differentially upregulated 
in liver metastasis when compared to the CRC primary tumor in orthotopically implanted 
xenograft mouse model. Further studies showed that ezrin plays a key role in CRC cell survival, 
and is downstream of the IGF1R signaling pathway. The third project (Chapter 4) focused on the 
mechanism behind the role of ezrin in CRC cell survival. This work led to the identification of a 
potential novel mechanism by which TGFβ/Smad3 and IGF1R signaling crosstalk with each 






















Figure 1.1.  Loss of normal growth control in cancer:  [Figure reproduced from National 






















































Figure 1.2.  Progression model depicting gene alteration in colorectal cancer: The Vogelgram 
model depicts colorectal cancer progression from the normal epithelium to cancer and the 
associated tumor suppressor genes and oncogenic genes that are lost and over expressed 
respectively, with disease progression. [Figure reproduced with permission from Markowitz SD, 
Bertagnolli MM. Molecular Basis of Colorectal Cancer. N Engl J Med 2009; 361:2449-2460, 









































Figure 1.3.  IGF1R signaling pathway: Ligand binding to the IGF1R promotes intrinsic 
tyrosine kinase activity and auto-phosphorylation. Activated receptors recruit and phosphorylate 
substrates such as IRS and Shc, leading to downstream signaling activation via two pathways 
(PI3K/Akt and Ras/MAPK pathways) coordinating downstream IGF’s bioactivities. [Figure 
reproduced with permission from Denduluri SK, Idowu O, Wang Z, et al. Insulin-like growth 
factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes & 

















































Figure 1.4.  TGFβ signaling pathway: Upon TGFβ1 binding to the receptor subunit TGFβRII, 
the TGFβRI receptor is recruited to the complex and phosphorylated (Steps 1& 2). Receptor 
Smads (R-Smad2/3) are translocated to the receptor complex (Step 3), phosphorylated, and form 
a heteromeric complex with cytosolic Smads (Smad4) (Steps 3&4). The Smad complex 
translocates to the nucleus and binds to Smad-binding elements (SBE) to activate or repress 
TGFβ-responsive-gene expression (Steps 5&6). [Figure reproduced with permission from 
Stephen J. Assinder, Qihan Dong, Zaklina Kovacevic, Des R. Richardson. The TGFβ, PI3K/Akt 
and PTEN pathways: established and proposed biochemical integration in prostate cancer. 










































Figure 1.5.  Cyclic AMP mediated PKA activation: Agonist stimulation of (a) Gα-containing 
G-protein-coupled receptors (GPCRs) activate adenylyl cyclase (AC), which catalyses the 
synthesis of cAMP from ATP. cAMP binds to the regulatory (R) subunits of protein kinase A 
(PKA) (b), which causes a conformational change that releases the active catalytic (C) subunit. 
The catalytic subunit of PKA can then phosphorylate nearby substrates. PKA represents the main 
intracellular effector of cAMP signaling. However, cAMP can also activate nucleotide-gated ion 
channels (c), phosphodiesterases (PDEs) such as PDE4 (d), and guanine nucleotide-exchange 
factors (GEFs) that are known as exchange proteins activated by cAMP (EPACs) (e). AKAP, A-
kinase anchoring protein. [Figure reproduced by permission from Macmillan Publishers Ltd: 
Nature Reviews Molecular Cell Biology, Wei Wong and John D. Scott. AKAP signalling 

































Figure 1.6.  Representation of the domain structure of AKAP: [Figure reproduced from 
McConnachie, G., L.K. Langeberg, and J.D. Scott, AKAP signaling complexes: getting to the 



















































Figure 1.7.  AKAP-mediated localization of PKA in different subcellular compartments: 
Schematic diagram of A-kinase anchoring proteins (AKAPs) targeting protein kinase A (PKA) to 
specific compartments, including the plasma membrane, mitochondria, cytoskeleton and 
centrosome. [Figure reproduced with permission from Macmillan Publishers Ltd: Nature Reviews 
Molecular Cell Biology, Wei Wong and John D. Scott. AKAP signalling complexes: focal points 



























































Figure 1.8.  Representation of the domain structure of ERM family of proteins: [Figure 
reproduced with permission from Macmillan Publishers Ltd: Nat Rev Mol Cell Biol, Anthony 
Bretscher, Kevin Edwards & Richard G. Fehon. ERM proteins and merlin: integrators at the cell 
































































Figure 1.9.  Mechanism of ezrin activation: ERM proteins exist in a dormant, monomeric form 
in which the FERM domain is associated with the COOH-terminal domain (a). Local production 
of phosphatidylinositol 3,4-bisphosphate (PtdIns(4,5)P2) recruits ezrin to the plasma membrane, 
which places them in a location to be phosphorylated, and thereby activated, by Rho-kinase or 
protein kinase C. Activated ezrin can then participate in microfilament–membrane linkage by 
direct association with transmembrane proteins (b), or indirectly through scaffolding molecules 
such as EBP50/NHERF and E3KARP (c). [Figure reproduced with permission from Macmillan 
Publishers Ltd: Nat Rev Mol Cell Biol, Anthony Bretscher, Kevin Edwards & Richard G. Fehon. 























































Figure 1.10.  Representation of the domain structure of mammalian IAP family of proteins.  
At present, there are eight members of the mammalian IAP family of proteins. Of these, XIAP 
and survivin are well characterized and have been implicated to play a role in cell survival and 
metastasis. [Figure reproduced with permission from Elena M. Ribe, Esther Serrano-Saiz, Nsikan 
Akpan, Carol M. Troy. Mechanisms of neuronal death in disease: defining the models and the 



















































IN VIVO ANALYSIS OF RECOMBINANT HUMANIZED IGF1R MONOCLONAL 
































The materials presented in this chapter were published: Leiphrakpam, P. D., Agarwal, E., Mathiesen, M., 
Haferbier, K. L., Brattain, M. G., Chowdhury, S. "In vivo analysis of insulin-like growth factor type 1 
receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in 
colorectal cancer". Oncology Reports 31.1 (2014): 87-94. 
37 
  
2.    In vivo analysis of recombinant humanized IGF1R monoclonal antibody MK-0646 and 
IGF1R small molecule inhibitor OSI-906 in colorectal cancer 
2.1.    Abstract 
The development and characterization of effective anticancer drugs against colorectal cancer 
(CRC) is of urgent need since it is the second most common cause of cancer death. The study was 
designed to evaluate the effects of two IGF1R antagonists, MK-0646, a recombinant fully human-
ized monoclonal antibody and OSI-906, a small molecule tyrosine kinase inhibitor on CRC cells. 
Xenograft study was performed on IGF1R-dependent CRC cell lines for analyzing the antitumor 
activity of MK-0646 and OSI-906. Tumor proliferation and apoptosis were assessed using Ki67 
and TUNEL assays, respectively. We also performed in vitro characterization of MK-0646 and 
OSI-906 treatment on CRC cells to identify mechanisms associated with drug-induced cell death. 
Exposure of the GEO and CBS tumor xenografts to MK-0646 or OSI-906 led to a decrease in 
tumor growth. TUNEL analysis showed an increase of approximately 45-55% in apoptotic cells 
in both MK-0646- and OSI-906-treated tumor samples. We report the novel finding that treatment 
with IGF1R antagonists led to downregulation of X-linked inhibitor of apoptosis (XIAP) protein 
involved in cell survival and inhibition of cell death. In conclusion, IGF1R antagonists (MK-0646 
and OSI-906) demonstrated single agent inhibition of subcutaneous CRC xenograft growth. This 
was coupled to pro-apoptotic effects resulting in downregulation of XIAP and inhibition of cell 
survival. We report a novel mechanism by which MK-0646 and OSI-906 elicits cell death in vivo 
and in vitro. Moreover, these results indicate that MK-0646 and OSI-906 may be potential 
anticancer candidates for the treatment of patients with IG-1R-dependent CRC. 
2.2.    Introduction 
The insulin-like growth factor receptor (IGF1R) is a receptor tyrosine kinase that is widely 
expressed in normal human tissues and upregulated in a number of human cancers including 
colorectal cancer (CRC) [127-129]. IGF1R is comprised of three components, two extracellular 
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α-chains, that are involved in ligand binding, two transmembrane spanning β-chains and an 
intracellular tyrosine kinase [20, 128, 130]. Both IGF1 and IGF2 are ligands for IGF1R and their 
binding induces receptor autophosphorylation at the tyrosine kinase domain, resulting in its 
activation by a conformational change leading to stimulation of signaling cascades, including 
PI3K/Akt and MAPK pathways [20, 130-133]. Activation of IGF1R has been reported to 
stimulate oncogenic cellular processes, including aberrant cell survival mechanisms, 
transformation, motility, angiogenesis and metastasis [128, 129, 134]. Previous work from our 
laboratory as well as other groups has shown that inhibition of IGF1R has been shown to impede 
tumorigenesis in several human xenograft models [128, 129, 134, 135]. 
             IGF1R plays a multifunctional role in human CRC growth and is widely regarded as an 
attractive target for anticancer drug treatment based on the observation that inhibition of IGF1R 
function results in apoptosis and inhibition of tumor growth. Several pharmacological strategies 
are currently being adopted in clinical trials to disrupt the IGF1R signaling pathway. This 
includes anti-receptor antibodies to reduce receptor expression, small-molecule IGF1R kinase 
inhibitors, and targeting downstream IGF1R signaling pathways with agents, such as Akt or 
mTOR inhibitors [134]. In this study, we characterized the in vivo and in vitro effects of MK-
0646, a novel IGF1R recombinant humanized monoclonal antibody. It has been reported that 
MK-0646 binds to IGF1R and triggers receptor internalization and degradation thereby blocking 
IGF1- and 2-mediated cellular proliferation and survival [136]. MK-0646 specifically targets 
IGF1R and does not cross-react with the insulin receptor [137]. It is in a phase II clinical trial at 
present [21, 138-140]. 
             OSI-906 is a potent and highly selective small molecule tyrosine kinase inhibitor which 
binds dually to IGF1R and IR and inhibits autophosphorylation [131, 132]. It is also in phase II 
clinical trials at present [21]. Initiation of apoptosis and inhibition of cell proliferation following 
OSI-906 treatment appears to be directly linked to Akt inhibition in various tumor cell lines 
including lung, pancreatic and CRC cell lines [131, 141]. In addition, OSI-906 has shown potent 
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antitumor activity in vivo in several xenograft models [142]. Buck et al. has shown that OSI-906 
reduces tumorigenicity in GEO CRC xenografts [142]. However, the signaling mechanisms 
associated with OSI-906-mediated cell death are poorly understood. 
             The goal of the present study was to compare the antagonistic effects of MK-0646 and 
OSI-906 in vivo and in vitro and characterize mechanisms associated with drug-induced cell 
death. We report for the first time the antitumor activity of MK-0646 in IGF1R-dependent CRC 
cells and demonstrate that inhibition of IGF1R leads to control of aberrant cell survival signaling 
through the downregulation of XIAP and induction of cell death. 
2.3.   Materials and Methods 
2.3.1.    Cell lines 
GEO and CBS cell lines used in this study were originally developed from primary CRC tumors 
and have been extensively characterized [143]. Cells were maintained at 37˚C in humidified 
atmosphere of 5% CO2 in a chemically defined serum-free medium consisting of McCoy's 5A 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with amino acids, pyruvate, 
vitamins, antibiotics and growth factors, transferrin (4 μg/ml; Sigma-Aldrich), insulin (20 μg/ml; 
Sigma-Aldrich), and EGF (10 ng/ml; R&D Systems) as previously described [144]. 
Supplemented McCoy's medium (‘SM’) is McCoy's 5A medium supplemented with antibiotics 
and nutrients but lacking any growth factors. Cells were routinely subcultured with 0.25% trypsin 
(Invitrogen, Carlsbad, CA, USA) in Joklik's medium (Invitrogen) containing 0.1% EDTA. When 
cells were under growth factor deprivation status (GFDS), they were cultured in SM medium 
without growth factor or serum supplements for the indicated time periods without medium 
change in between. 
2.3.2.    Antibodies                                                                                                                                                                               




Inc. Beverly, MA, USA) (Beverly, MA, USA). XIAP antibody was obtained from Abcam. β-
actin and GAPDH antibodies were from Sigma-Aldrich (St. Louis, MO, USA). 
 2.3.3.   Pharmacological antagonists 
MK-0646 was provided by Merck & Co. (Whitehouse Station, NJ, USA) and OSI-906 was 
purchased from Chemitek, Indianapolis, IN, USA. 
2.3.4.    Xenograft experiments 
All experiments involving animals were approved by the University of Nebraska Medical Center 
Institutional Animal Care and Use Committee. The GEO and CBS cells were transfected with 
green fluorescence protein (GFP). Exponentially growing GFP-labeled GEO and CBS cells (~7 
million cells/ml SF media) were inoculated subcutaneously onto the dorsal surfaces of athymic 
nude male mice and the growth of the tumor was monitored by biweekly measurements using a 
caliper. Once xenografts were established (~50-100 mm3), MK-0646 or OSI-906 treatment was 
initiated and continued for two weeks. MK-0646 was given by intraperitoneal (IP) injection 
weekly (20 mg/kg) on both GEO and CBS xenografted mice for three doses and formulation 
buffer was the vehicle. OSI-906 was given by daily oral gavage (40 mg/kg) on GEO xenografted 
mice and tartaric acid was the vehicle. Xenografts were harvested after 14 days of treatment for 
assessment of molecular effects by the two agents. 
 2.3.5.   Xenograft lysate preparation 
Xenografts were harvested and snap frozen in liquid nitrogen and stored at -80̊C. Xenografts were 
first washed in cold 5% PBS and collected in lysis buffer [50 mmol/l Tris (pH 7.4), 100 mmol/l 
NaCl, 1% NP40, 2 mmol/l EDTA, 0.1% SDS, 50 mmol/l NaF, 10 mmol/l Na3VO4, 1 mmol/l 
phenylmethylsulfonyl fluoride, 25 μg/ml β-glycerophosphate, and one protease inhibitor cocktail 
tablet from Roche]. Crude xenograft lysates were homogenized to shear DNA and lysed for 30 
min on ice. Xenograft lysates were then cleared by centrifugation at 13000 rpm for 20 min at 4˚C. 
Protein concentrations were determined by the Pierce bicinchonimic acid protein assay (Pierce 
Biotechnology, Inc., Rockford, IL, USA). 
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2.3.6.    Cell lysate preparation 
GEO CRC cells were allowed to grow until 70-80% confluent in 100-mm culture plates and were 
treated with different concentrations of either MK-0646 or OSI-906 under growth factor 
deprivation status (GFDS) for 48 h. Cells were washed in cold 5% PBS and collected in lysis 
buffer. Crude cell lysates were homogenized using a 21-gauge needle to shear DNA and lysed for 
30 min on ice. Cell lysates were then cleared by centrifugation at 13000 rpm for 20 min at 4˚C. 
Protein concentrations were determined by the Pierce bicinchonimic acid protein assay (Pierce 
Biotechnology, Inc.). 
2.3.7.    Western blot analysis 
Protein (30-100 μg) was fractionated on an acrylamide denaturing gel and transferred onto a 
nitrocellulose membrane (Amersham Biosciences) by electroblotting. The membrane was 
blocked with 5% nonfat dry milk in 1X TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% 
Tween-20) for 1 h at room temperature or overnight at 4˚C. The membrane was then incubated 
with primary antibodies for 1 h at room temperature or overnight at 4˚C with 5% nonfat dry milk 
in 1X TBST or 5% bovine serum albumin (BSA) in 1X TBST according to the manufacturer's 
instructions. After washing three times with 1X TBST for 10 min each, the membrane was 
incubated with horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) 
for 1 h at room temperature. After further washing in 1X TBST three times for 10 min each, the 
proteins were detected by the enhanced chemiluminescence system (Amersham Biosciences). 
2.3.8.    Apoptosis assay 
DNA fragmentation assays were performed on cells treated with either MK-0646 or OSI-906 
under GFDS. Cells were seeded in 96-well plates and allowed to grow to 70-80% confluence. 
The cells were then changed to Supplemented McCoy's medium (‘SM’) and treated with various 
concentrations of either MK-0646 or OSI-906 for 48 h. Assays were then performed using a cell 
death ELISA kit (Roche Applied Science) according to the manufacturer's protocol as previously 
described [145]. The plate was read at 405 nm. Inhibition of proliferation was assessed by the 
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MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay as previously 
described [29] 
 2.3.9.   Cell cycle arrest analysis 
GEO CRC cells were allowed to grow until 70-80% confluent in 100-mm culture plates and were 
treated with different concentrations of either MK-0646 or OSI-906 under growth factor 
deprivation status (GFDS) for 48 h and cell cycle analysis was performed as previously described 
[146]. 
2.3.10.  Hematoxylin and eosin, TUNEL and Ki67 staining 
Xenografts obtained from subcutaneous injection of GEO cells were harvested and placed in 10% 
neutral buffer formalin fixative for 12-24 h and then embedded in paraffin. Sections (4 μm) were 
cut from paraffin-embedded blocks using a microtome and were used for hematoxylin and eosin 
stains and immunohistochemical characterizations. Serial sections were cut to complement the 
hematoxylin and eosin sections and were stained with the Apo-tag (Millipore) terminal 
nucleotidyl transferase mediated nick end-labeling (TUNEL) kit following the manufacturer's 
protocol. The apoptotic rate was determined semi-quantitatively by counting the number of 
positively stained apoptotic bodies per 75-μm
2
 field at a magnification of X20. Approximately 
1000 total cells were counted and the percentages of positively stained cells were calculated. Four 
control and four treated slides for MK-0646 and OSI-906 were analyzed, respectively. Staining 
was also performed with IgG1 rabbit polyclonal antibody for Ki67 (Dako Corp.). Ki67 is a non-
histone nuclear antigen present in late G1, G2, and S phases of the cell cycle but not in G0. A 
1:20 dilution was used and staining was performed following the manufacturer's protocol. The 
proliferation rate was determined semi-quantitatively by counting the number of positively 
stained proliferative cells per 75-μm² field at a magnification of x20. Approximately 1000 total 
cells were counted and the percentages of positively stained cells were calculated. Four control 




2.3.11.  Immunohistochemistry 
Sections (4 μm) were cut from the paraffin-embedded xenograft tumor blocks, deparaffinized in 
histoclear, and rehydrated in descending grades of ethanol. Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide in water. Immunostaining was performed for XIAP using an 
indirect detection method [147]. The staining was accompanied by a negative control in which 
slides were incubated with a matching blocking peptide to the primary antibody. Slides were 
counterstained with hematoxylin. Specimens were processed on the same day to eliminate any 
variability in conditions. Slides were digitally photographed using the same settings. 
2.3.12.  Statistical analysis 
Statistical significance was determined using two-tailed Student's t-test with a p-value <0.05. All 
the experiments were repeated three times independently to determine consistency in the results. 
The results were expressed as mean ± SE for three replicates for each treatment. 
2.4.    Results 
2.4.1.    Inhibition of IGF1R is associated with antitumor activity in vivo 
The antitumor effects were determined in the IGF1R-dependent CRC subcutaneous xenograft 
tumors following treatment with IGF1R antagonist MK-0646 or OSI-906. MK-0646 treatment for 
three weeks at 20 mg/kg dose once weekly inhibited the growth of the GEO xenograft tumors 
(Fig. 1A and B). Similar results were obtained in MK-0646 treated CBS xenograft tumor (data 
not shown). The final tumor volume and weight were significantly reduced in MK-0646 treated 
xenografts compared with the control (Fig. 1C and D). Results obtained by daily treatment of 
OSI-906 (40 mg/kg) for two weeks orally (Fig. 2A and B) were comparable to the MK-0646 
treated tumor xenografts showing decrease in tumor growth. However, we observed ~10% body 
weight reduction in OSI-906 treated mice compared with the MK-0646 treated mice (data not 




2.4.2.    IGF1R inhibition of apoptosis in vivo and in vitro 
We assessed the apoptosis level of control and drug-treated xenografts using TUNEL assays. 
Comparable results were obtained for both IGF1R antagonists. Both MK-0646- and OSI-906-
treated GEO xenografts had statistically significant increase in apoptosis (p<0.05) as compared 
with the control tumors (Fig. 3A-D). Based on the pro-apoptotic effects of both MK-0646 and 
OSI-906 in vivo, DNA fragmentation was performed in vitro on GEO CRC cells to determine cell 
death following IGF1R antagonist treatment (Fig. 3E and F). In accordance with the in vivo study, 
both MK-0646 and OSI-906 treatment showed significant increases in apoptosis demonstrating 
that IGF1R inhibition elicits pro-apoptotic effects on CRC cells. 
2.4.3.    IGF1R inhibition of cell proliferation in vivo and in vitro 
Ki67 staining was performed to assess the proliferation level on MK-0646- and OSI-906-treated 
GEO xenografts. MK-0646-treated GEO xenografts showed no change in the cell proliferation 
compared with the control (Fig. 4A and B). However, OSI-906-treated GEO xenografts showed a 
statistically significant reduction (p<0.05) in cell proliferation compared with the control (Fig. 4C 
and D). We also assessed cell proliferation of GEO CRC cells in vitro by MTT assay after 
treating with different concentrations of MK-0646 or OSI-906. OSI-906 treatment showed a 
decrease in cell proliferation (Fig. 4E), altered cell cycle in G0/G1 phase (Fig. 5A), and showed a 
decrease in the 4N DNA content (Fig. 5B and C). However, MK-0646 treatment showed no effect 
on cell cycle (data not shown). OSI-906 treatment also led to increase in p21 expression (Fig. 
5D). 
2.4.4.    IGF1R treatment in vivo and in vitro decreases downstream substrates 
Previous studies have shown that IGF1R signaling exerts its anti-apoptotic effect through the 
IRS1/IRS2/PI3K/Akt pathway [26, 148-150]. We determined the effects of MK-0646 and OSI-
906 on the IGF1R and its downstream signaling pathways on control and treated GEO CRC 
xenografts. The xenograft tumor samples were analyzed for the expression of molecules 
associated with the IGF1R signaling pathway, including IGF1Rβ (Y1135), Akt, and pAkt (S473). 
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Inhibition of IGF1R by MK-0646 and OSI-906 led to the downregulation of IGF1R and its 
phosphorylation (Fig. 6A and B), confirming the inhibitory effect of both antagonists on IGF1R 
signaling. IGF1R inhibition by MK-0646 or OSI-906 showed dephosphorylation of Akt at S473 
site (data not shown). We next determined the effects of IGF1R inhibition in vitro, using GEO 
cells following treatment with either MK-0646 or OSI-906. GEO cells were treated with MK-
0646 or OSI-906 under GFDS conditions. Both MK-0646 and OSI-906 showed similar response 
on IGF1R and pIGF1R in vitro (data not shown). Additionally, marked reduction in pAkt (S473) 
was also observed in MK-0646- (20 μg/ml) or OSI-906- (0.5 μM) treated cells (data not shown). 
These results showed that both antagonists MK-0646 and OSI-906 effectively inhibited IGF1R 
and its downstream signaling. 
2.4.5.     IGF1R inhibition downregulates the IAP molecule XIAP in vivo and in vitro 
XIAP, an IAP (inhibitor of apoptosis) molecule and a key cell survival protein for inhibition of 
caspases, is a physiological substrate of Akt [151]. Akt phosphorylates XIAP at Ser87 and 
regulates its autoubiquitination and degradation, and thereby stabilizes XIAP [151]. Chowdhury 
et al. have shown that XIAP is associated with p-Akt and this association is disrupted following 
TGFβ treatment, leading to XIAP degradation [16]. Moreover, XIAP and survivin form a 
complex in the cytosol and this complex inhibits caspase activity as well as cell death and 
promotes tumor growth in vivo [124] Inhibition of the aberrant cell survival signaling of XIAP 
through destabilization of XIAP/survivin complexes leads to caspase reactivation and cell death 
[16, 152]. We demonstrated that IGF1R signaling pathway inhibition either by MK-0646 or OSI-
906 both in vivo and in vitro downregulated Akt signaling, and this inhibition in turn leads to the 
downregulation of XIAP by immunohistochemical and western blot analysis (Fig. 7A-D). Next, 
we treated GEO cells with the IGF1R antagonist in vitro for 48 h. Similar to the in vivo results, 
MK-0646 and OSI-906 both showed XIAP downregulation in the treated lysates compared to the 
control (Fig. 7E and F). These results showed that both antagonists exhibited their pro-apoptotic 
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mechanism through inhibition of XIAP, an important downstream cell survival pathway molecule 
required for the survival of the IGF1R-dependent CRC cells. 
2.5.    Discussion 
Aberrant regulation of growth factors and their corresponding receptors play important roles in 
malignant progression [153-158]. IGF1R signaling pathway is prevalent in many cancers, 
including CRC [159-161]. The IGF1R gene has been reported to be overexpressed in human CRC 
[156] with ~30-40% of all CRC being IGF1R-dependent [29, 162]. Therefore, the IGF1R 
signaling pathway is under intense investigation as an attractive candidate for the development of 
novel therapeutic strategies for anticancer treatment. 
             Buck et al. inhibited the IGF1R signaling pathway using OSI-906 in GEO xenograft 
tumors [142]. It was reported that OSI-906 inhibited the growth of the GEO xenografts [142]. 
Recently, we demonstrated that IGF1R kinase inhibitor PQIP causes marked antitumor activity in 
these colon cancer cell lines by abrogating the IGF1R mediated activation of IRS1/Akt to inhibit 
survival signaling, and inducing apoptosis [135]. In the present study, we analyzed the antitumor 
activity of a novel recombinant humanized monoclonal antibody, MK-0646, in CRC cells both in 
vivo and in vitro in comparison to OSI-906. Monoclonal antibodies against IGF1R share a 
common mechanism of action, involving blockade of ligand-receptor interactions and decreased 
cell surface receptor through receptor internationalization and downregulation of the receptor 
[136, 163-165]. This leads to blockade of the PI3K/Akt signaling pathway [22, 163-165]. 
However, mechanisms associated with IGF1R antagonist-mediated cell death are poorly 
understood. Our data demonstrated that MK-0646 decreased tumor growth in CRC xenografts in 
vivo and is supported by downregulation of IGF1R and pIGF1Rβ in western blot analysis. MK-
0646 demonstrated similar antitumor activity when compared to OSI-906. 
             IGF1R signaling exerts its anti-apoptotic effect through the IRS1/IRS2/PI3K/Akt 
pathway [26, 29, 135, 148-150]. We observed downregulation of IRS-1/2 and pAkt (S473) and 
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significant increase in tumor cell apoptosis after MK-0646 or OSI-906 treatment. Akt and its 
downstream molecular targets constitute a major cell survival pathway [166]. XIAP, a pro-
survival IAP, is a physiological substrate of Akt [151]. Akt phosphorylates XIAP at Ser87 and 
reduces its degradation, conferring resistance to caspase activation and apoptosis [151]. 
Deregulation of IAP functions aberrantly prolonging cancer cell viability, and XIAP and survivin 
have been recognized for their roles in tumor formation and are targets for cancer therapeutics 
[124]. We made the novel observation that XIAP, a critical cell survival molecule that counteracts 
caspase activation and induction of apoptosis [124, 151] is downregulated with both MK-0646 
and OSI-906 treatments, demonstrating that XIAP is downstream of IGF1R/Akt-mediated control 
of aberrant cell survival responses. XIAP has been linked to cell survival and metastasis [114]. 
XIAP/survivin complexes that mediate caspase inhibition have been shown to be a key cell 
survival mechanism for supporting the metastatic process [124]. Previous studies in our 
laboratory have shown that destabilization of XIAP/survivin complexes by the TGFβ tumor 
suppressor signaling leads to inhibition of aberrant cell survival resulting in cell death [16, 152]. 
Therefore, the IGF1R signaling pathway and its downstream cell survival mediator XIAP may be 
potential dual targets for anticancer therapy. 
In conclusion, this study demonstrated that MK-0646, a novel humanized IGF1R monoclonal 
antibody, has comparable antitumor effects to IGF1R small molecule inhibitor OSI-906, and may 
be a potential novel targeted therapy against the IGF1R-dependent subset of human CRC. 
Therefore, the results obtained in this study utilizing IGF1R antagonists provide a rationale for 
further pre-clinical studies in order to dissect the IGF1R signaling pathway to obtain full benefit 
from this receptor targeted therapy as a single agent or in combination against CRC as well as 
other solid tumors dependent upon IGF1R signaling. 




Figure 2.1.  In vivo analysis of IGF1R inhibition using MK-0646 on tumor growth and 
weight in GEO CRC xenografts: Significant decrease of the tumor volume and weight was 
observed in MK-0646-treated xenografts compared with the control (A, B, C and D). (n=14, 








































Figure 2.2.   In vivo analysis of IGF1R inhibition using OSI-906 on tumor growth and 
weight in GEO CRC xenografts: Significant decrease of the tumor volume was observed in 


















































Figure 2.3.  IGF1R inhibition on apoptosis in vivo and in vitro: TUNEL assay was performed 
on both MK-0646 and OSI-906 treated and control xenograft paraffin-embedded slides and 
statistical analysis was determined (A, B, C and D). GEO cells were grown to 70-80% confluency 
and treated with different doses of either MK-0646 or OSI-906 under GFDS for 48 h and the 









































Figure 2.4.  IGF1R inhibition on cell proliferation in vivo and in vitro: Ki-67 staining was 
performed on both MK-0646- and OSI-906-treated and control xenograft paraffin-embedded 
slides and statistical analysis was determined (A, B, C and D). In order to determine the in vitro 
effects of IGF1R inhibition on proliferation, the MTT assay was performed with different doses 










































Figure 2.5.  Effects of IGF1R inhibition on cell cycle in vitro: GEO CRC cells were grown to 
70-80% confluence, treated with OSI-906 under GFDS for 48 h, and cell cycle analysis as 
explained in Materials and Methods (A-C). Western blot analysis was performed on the OSI-906 











































Figure 2.6.  IGF1R inhibition in vivo and in vitro decreases downstream substrates: GEO 
xenografts of both MK-0646 and OSI-906 were homogenized and western blot analyses were 
performed with antibodies to IGF1Rβ and pIGF1Rβ (Y1135). Actin and GAPDH were used as 





















































Figure 2.7.  IGF1R inhibition downregulates the IAP molecule XIAP in vivo and in vitro: 
Immunohistochemical analysis of XIAP protein was performed on both MK-0646- and OSI-906-
treated paraffin-embedded xenografts. To confirm antibody specificity, a blocking peptide was 
used (A and B). Control and MK-0646- or OSI-906-treated GEO xenografts were analyzed by 
western blotting using anti-XIAP antibody (C and D). For in vitro analysis, GEO CRC cells were 
grown to 70-80% confluence and treated with either MK-0646 or OSI-906 under GFDS for 48 h. 
Cells were harvested as described in Materials and Methods and western blot analyses were 
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3.    Ezrin expression and cell survival regulation in colorectal cancer 
3.1.    Abstract 
Colorectal cancer (CRC) is the second largest cause of cancer deaths in the United States. A key 
barrier that prevents better outcomes for this type of cancer as well as other solid tumors is the 
lack of effective therapies against the metastatic disease. Thus there is an urgent need to fill this 
gap in cancer therapy. We utilized a 2D-DIGE proteomics approach to identify and characterize 
proteins that are differentially regulated between primary colon tumor and liver metastatic 
deposits of the IGF1R-dependent GEO human CRC xenograft, orthotopically implanted in 
athymic nude mice that may serve as potential therapeutic targets against CRC metastasis. We 
observed increased expression of ezrin in liver metastasis in comparison to the primary colonic 
tumor. Increased ezrin expression was further confirmed by western blot and microarray analyses. 
Ezrin, a cytoskeletal protein belonging to ezrin–radixin–moesin (ERM) family plays important 
roles in cell motility, invasion and metastasis. However, its exact function in colorectal cancer is 
not well characterized. Establishment of advanced GEO cell lines with enhanced liver-
metastasizing ability showed a significant increase in ezrin expression in liver metastasis. 
Increased phosphorylation of ezrin at the T567 site (termed here as p-ezrin T567) was observed in 
liver metastasis. IHC studies of human CRC patient specimens showed an increased expression of 
p-ezrin T567 in liver metastasis compared to the primary tumors of the same patient. Ezrin 
modulation by siRNA, inhibitors, and T567A/D point mutations significantly downregulated 
inhibitors of apoptosis (IAP) proteins XIAP and survivin that have been linked to increased 
aberrant cell survival and metastasis and increased cell death. Inhibition of the IGF1R signaling 
pathway by humanized recombinant IGF1R monoclonal antibody MK-0646 in athymic mouse 
subcutaneous xenografts resulted in inhibition of p-ezrin T567, indicating ezrin signaling is 
downstream of the IGF1R signaling pathway. We identified increased expression of p-ezrin T567 
in CRC liver metastasis in both orthotopically implanted GEO tumors as well as human patient 
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specimens. We report for the first time that p-ezrin T567 is downstream of the IGF1R signaling 
and demonstrate that ezrin regulates cell survival through survivin/XIAP modulation. 
3.2.    Introduction 
Metastasis to distant organs is mainly responsible for the cancer-related deaths from solid tumors, 
including colorectal cancer (termed as CRC) [5, 11]. This is due to the lack of effective therapies 
against the disseminated disease. Thus, there is an urgent need to fill this gap in cancer therapy. 
Therefore, understanding the mechanisms associated with metastatic progression is critical for 
developing anti-metastatic therapies. Various “omics” based analyses have emerged as key 
players for the identification of potential targets for the development of new therapies against 
cancers [167-170]. In the post genome era, proteomics has developed as a powerful tool for the 
characterization of normal and abnormal cellular functions associated with malignant 
transformation, for the discovery of critical disease-specific targets, and identification of novel 
endpoints for the study of chemotherapeutic agents and its associated toxicity [170]. The study of 
the proteome, which is the functional translation of the genome, is directly linked to specific 
phenotypes [171]. 
             The proteomic background of CRC has been extensively characterized under different 
conditions using different proteomic approaches (including gel-based separation methods, mass 
spectrometry, and array-based methods) to identify several proteins involved in the initiation and 
progression of CRC[171]. Additionally, proteomic studies have helped provide significant insight 
into the understanding of cellular functions associated with normal and diseased conditions [169-
172]. Ying - Taoa et al. (2005) utilized a two dimensional electrophoresis (2-DE) method to 
compare metastatic LS174T and non-metastatic SW480 CRC cell lines to explore their 
differences in protein expression that might be linked to CRC metastasis. The proteins, platelet-
derived endothelial cell growth factor (PDECGF), septin, and cell division cycle 2 (cdc2) were 
observed to be highly expressed in the metastatic cell lines [173]. Shi-Yong Li et al. (2010) used 
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a 2D-DIGE (2-dimensional difference in-gel electrophoresis) approach to investigate the 
differential expression of proteins in human CRC patients with liver metastasis to evaluate its 
clinical diagnostic potential [174]. They compared protein expression between normal mucosa, 
primary colonic carcinoma and liver metastasis specimens. It was reported that zinc finger protein 
64 homolog (Zfp64), guanine nucleotide exchange factor 4 (GEF4), human arginase, glutathione 
S-transferases (GSTs) A3, and tumor necrosis factor α (TNF-α)-induced protein 9 are upregulated 
in human CRC liver metastasis [174]. Recently, Sugihara et al.. (2012) identified APC-binding 
protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer 
using the 2D-DIGE/MS (mass spectrometry) approach [171]. 
             In this study, the 2D-DIGE/MS method was used to identify potential molecular targets 
associated with liver metastasis originating from primary colon carcinoma generated by the 
orthotopic mouse metastasis model developed in our laboratory [12, 14-16, 135, 175-178]. Highly 
metastatic IGF1R-dependent GEO human CRC xenograft tumors were implanted orthotopically 
in the colon of athymic nude mice to generate spontaneous liver metastasis [16, 29]. We 
compared the global protein expression of primary colon carcinoma and liver metastases of GEO 
cells and identified an increased expression of ezrin and its phosphorylation at T567 (termed here 
as p-ezrin T567) in liver metastasis compared to the primary tumor. Previous studies have shown 
that ezrin plays a critical role in tumorigenesis and has been implicated in metastasis of several 
types of cancers including CRC [83, 84, 87, 107, 179]. We performed in vitro characterization of 
ezrin in CRC cells and identified IGF1R-p-ezrin T567-XIAP axis as a potential cell survival 
pathway target in IGF1R-dependent subsets of CRC cells. Ezrin and p-ezrin T567 appear to have 
a key role in the regulation of IGF1R-dependent CRC cell survival properties that may ultimately 
be utilized for the identification of novel anti-metastatic therapies. 
3.3.    Material and Methods 
3.3.1.    Cell lines 
66 
  
GEO, GEORI, CBS, HCT166 and HCT166b CRC cell lines were originally developed from 
primary CRC tumors and have been extensively characterized in our laboratory [143, 180-182]. 
Cells were maintained at 37 °C in humidified atmosphere in a chemically defined serum free 
medium consisting of McCoy's 5A medium (Sigma-Aldrich) supplemented with amino acids, 
pyruvate, vitamins, antibiotics, and growth factors transferrin (4μg/mL; Sigma-Aldrich), insulin 
(20 μg/mL; Sigma-Aldrich), and EGF (10 ng/mL; R&D Systems). Supplemented McCoy's 
medium (“SM”) is McCoy's 5A medium supplemented with antibiotics and nutrients but lacking 
any growth factors. 
 3.3.2.   Antibodies 
The following primary antibodies were obtained from Cell Signaling Biotechnology (Danvers, 
MA): IGF1Rβ (catalog#3027), p-IGF1Rβ (Y1135) (catalog#3918), p-ezrin/ERM(T567) 
(catalog#3149). The following primary antibodies were obtained from Santa Cruz Biotechnology 
(Dallas, TX): Ezrin (catalog#sc-71082) and survivin (catalog#sc-17779). XIAP 
(catalog#ab28151) was obtained from Abcam (Cambridge, MA). β-Actin (catalog#A2066) and 
GAPDH (catalog#G8795) were obtained from Sigma-Aldrich (St. Louis, MO).  
3.3.3.    Pharmacological antagonists 
Recombinant humanized IGF1R monoclonal antibody MK-0646 was provided by Merck 
Oncology and small molecule tyrosine kinase inhibitor OSI-906 was obtained from Chemietek. 
The ezrin inhibitors NSC668394 and NSC305787 were kindly provided by the Drug Synthesis 
and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatments and 
Diagnosis, National Cancer Institute. 
3.3.4.    Orthotopic implantation 
All the experiments involving animals were approved by the University of Nebraska Medical 
Center Institutional Animal Care and Use Committee. The orthotopic implantation methodology 
has been described in detail in previous studies from Brattain laboratory [12, 14, 16, 135, 175-
178]. Briefly, GEO and CBS cells were transfected with green fluorescence protein (GFP). 
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Exponentially growing GFP-labeled GEO and CBS cells (approximately7 million cells/mL 
Serum Free media) were inoculated subcutaneously onto the dorsal surfaces of athymic nude 
male mice. Once xenografts were established, approximately 500 mm3 in size, they were excised 
and minced into 1–2 mm3 pieces. Two of these pieces were then orthotopically implanted into 
other athymic nude mice. Approximately 60 days’ post-implantation, animals were euthanized. 
Organs were explanted, imaged, washed in chilled 1X PBS and immediately placed in liquid 
nitrogen and 10% formalin respectively. 15–30 mg of primary and liver metastasis tissues 
obtained after orthotopic implantation of GEO cells was shipped in dry ice to Applied Biomics, 
Inc. for proteomic analysis. 
3.3.5.    Enhancement of CRC liver-metastatic ability by serial passaging 
Previous studies have shown that training of CRC cell lines to be more aggressive through serial 
passaging of vertical selection of metastatic cells to initiate primary tumors leads to enhancement 
of metastatic capability [183, 184]. In our study, an orthotopic implantation procedure was 
performed using GEO CRC cells and the metastatic liver tissues were harvested. The tissues were 
homogenized and the metastatic cells were grown in tissue culture. This was followed by the 
subcutaneous dorsal injection of the metastatic cells to another nude mouse which was 
subsequently orthotopically implanted to initiate primary colon tumors. The whole procedure was 
repeated for 6 cycles of vertical selection of IGF1R-dependent GEO liver metastases to initiate 
primary tumors, and thus the highly aggressive cell lines after 6th passage termed as GEO Met6 
was obtained. 
3.3.6.    Two-dimensional differential in-gel electrophoresis (2D-DIGE) and mass 
spectrometry 
The 2D-DIGE and matrix-assisted laser desorption ionization time of flight mass spectrometry 
(MALDI/TOF MS) was performed by Applied Biomics, Inc. (Hayward, CA) [185, 186]. 
3.3.7.    Microarray analysis 
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Microarray analysis was performed on the orthotopically implanted GEO CRC primary tumor 
and liver metastasis using the Illumina platform. 
3.3.8.    Tissue and cell lysate preparation 
Orthotopically implanted primary tumor and liver metastasis tissues were harvested and snap 
frozen in liquid nitrogen and stored in −80 °C. Tumor tissues were first washed in cold 5% PBS 
and collected in lysis buffer [50 mmol/L Tris (pH 7.4), 100 mmol/L NaCl, 1% NP40, 2 mmol/L 
EDTA, 0.1% SDS, 50 mmol/L NaF, 10 mmol/L Na VO₄, 1 mmol/L phenylmethylsulfonyl 
fluoride, 25 μg/mL β-glycerophosphate, and one protease inhibitor cocktail tablet from Roche]. 
The CRC cells were washed in cold 5% PBS and collected in lysis buffer. Crude tissue lysates 
were homogenized using a homogenizer to shear DNA and lysed for 30 min on ice at 4 °C. The 
crude cell lysates were homogenized using a 21 gauge needle to shear DNA and lysed for 30 min 
on ice at 4 °C. Both tissue and cell lysates were then centrifuged at 13000 rpm for 20 min at 4 °C 
to clear them. Protein concentrations were determined by the bicinchoninic acid protein assay 
method (Pierce Biotechnology). 
3.3.9.    Transient knockdown of ezrin 
On-TARGETplus SMARTpool ezrin siRNA (L-017370-00-0005) was purchased from 
Dharmacon (Thermo Fisher Scientific Inc., USA) and knockdown was performed according to 
the manufacturer's protocol for GEO and CBS CRC cells. 
 3.3.10. Apoptosis assay 
DNA fragmentation assay was performed on GEO and CBS CRC cells with ezrin siRNA 
knockdown and control. Cells were seeded in 96 well plates and treated with ezrin siRNA the 
next day at 60–70% confluency for 48 h following the manufacturer's protocol. Assays were then 
performed using a cell death ELISA kit (Roche Applied Science) according to the manufacturer 
protocol as described in [145] and the plate was read at 405 nm. Inhibition of proliferation was 




3.3.11.  Western blot analyses 
Protein (30–100 μg) was fractionated by SDS-PAGE and transferred onto a nitrocellulose 
membrane (Amersham Biosciences) by electroblotting. The membrane was blocked with 5% 
nonfat dry milk in 1X TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween20) for 1 h at 
room temperature or overnight at 4 °C. The membrane was then incubated in primary antibodies 
for 1½ h at room temperature or overnight at 4 °C with 5% nonfat dry milk in 1X TBST or 5% 
bovine serum albumin (BSA) in 1X TBST according to the manufacturer's directions. The 
membrane was washed three times with 1X TBST for 10 min each and incubated with 
horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) for 1 h at room 
temperature. This was followed by washing again in 1X TBST as before and proteins were 
detected by an enhanced chemiluminescence system (Amersham Biosciences). 
3.3.12.  Hematoxylin and eosin and immunohistochemistry 
Orthotopically implanted animals were euthanized following proper IACUC protocol. Colon 
primary tumors and liver metastases obtained from orthotopical implantation were harvested, 
imaged, and immediately placed in 10% neutral buffer formalin fixative for 12 to 24 h. This was 
followed by further tissue processing and embedment in paraffin as blocks. 4 μm sections were 
cut from this the paraffin embedded blocks using a microtome for hematoxylin and eosin (H&E) 
staining. Serial sections were cut to complement the H&E sections and were used for 
immunohistochemical (IHC) characterizations. These slides were deparaffinized in Histoclear, 
and rehydrated in descending grades of ethanol and blocked for endogenous peroxide with 30% 
hydrogen peroxide. Immunostaining was done for ezrin and p-ezrin T567 using an indirect 
detection method. The staining was accompanied by negative controls in which slides were 
incubated with a matching blocking peptide to the primary antibody for p-ezrin T567 and with 1X 
TBST for ezrin. Slides were counterstained with hematoxylin. Specimens were processed on the 
same day to eliminate any variability in conditions. Whole slide scanning was performed using 
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Ventana's Coreo Au Slide Scanner in UNMC Tissue Science Facility and staining density was 
measured and quantified with ImagePro plus 7.0. 
3.3.13.  Paraffin embedded human tissue specimens  
All the experiments involving human specimens were approved by the University of Nebraska 
Medical Center Institutional Review Board (IRB). Paraffin embedded human CRC specimens 
were retrospectively obtained from the UNMC formalin fixed tissue science core and ezrin and p-
ezrin T567 IHC analysis was performed. 
3.3.14.  Colon tissue microarray (TMA) 
Colon TMAs were purchased from the National Cancer Institute. Briefly, colon TMAs consist of 
4 case sets with each set consisting of 119–120 colon tissue specimens representing the different 
colon cancer stages, normal colon epithelium (obtained from colon cancer or non-cancer 
diverticulitis surgeries), and tissues from adenomatous colon polyps. IHC analysis was performed 
on the colon TMAs for both ezrin and p-ezrin T567. 
3.3.15.  TUNEL and Ki67 staining 
Paraffin-embedded slides were stained with the Apo-tag (Milipore) terminal nucleotidyl 
transferase-mediated nick and labeling (TUNEL) kit for apoptosis and IgG rabbit polyclonal 
antibody for Ki67 (Dako Corporation) at 1:20 dilution for proliferation according to our 
established protocol [14,16]. The apoptotic and proliferation rates were determined semi-
quantitatively by counting the number of positively stained apoptotic and proliferative cells per 
75-μm
2
 field at X20 magnification respectively. Approximately 1000 total cells were counted and 
the percentages of positively stained cells were calculated. 
3.3.16.  Statistical analysis 
Statistical significance was determined using two-tailed Student's t test with a P value less than 
0.05 using the Graphpad Prism 5. All the experiments were independently repeated three times to 
determine consistency in the results. 
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3.4.    Results 
3.4.1.    Increased expression of ezrin is associated with liver metastasis 
Earlier work from our laboratory has demonstrated the high metastatic capability of the IGF1R-
dependent GEO human CRC cells [16, 29]. Using the orthotopic implantation model that we have 
extensively described in previous studies [15, 16, 135, 175-178, 187, 188], GEO primary colon 
carcinoma and liver metastasis were obtained, as shown in Figure 1A. The protein lysates from 
the tumors were compared for their global protein expression by 2D-DIGE (performed at Applied 
Biomics, Inc.). CRC primary tumors and liver metastasis were labeled with Cy3 (green) and Cy5 
(red) dyes respectively and 2D-DIGE analysis was performed, as shown in Figure 1B. Candidate 
protein spots were automatically selected by DeCyder software. Several protein spots showed 
differential expression between the primary colonic tumor and the liver metastasis (data not 
shown). Figure 1C and D show the high expression of a candidate protein in liver metastatic 
specimens in comparison to primary colonic carcinoma. The candidate protein was identified by 
mass spectrometry as ezrin, a cytoskeleton protein that belongs to the ezrin–radixin–moesin 
(ERM) family of proteins, which share approximately 75% sequence homology [64, 66]. Detailed 
information on the MALDI–TOF/MS result identifying the candidate protein as ezrin has been 
shown in Appendix A. Table S3.1. It is important to note that several proteins were detected in 
spot no. 2 which was identified as ezrin by mass spectrometry (Appendix A. Table S3.1). Since 
protein overlapping in spots is common to gel-based proteomics analysis [7], the protein with top-
ranked Mascot score was selected for further confirmation by western blotting, IHC and 
microarray analysis. The individual gel images and overlay of primary colon carcinoma and liver 
metastasis have been shown in Figure 2. 
3.4.2.    Elevated levels of ezrin phosphorylation at T567 site in liver metastasis 
Ezrin is present in a dormant state in the cytoplasm [77, 78, 90] and is activated through PIP2 
binding and phosphorylation at the T567 site [88, 89]. Previous studies have linked ezrin 
hyperphosphorylation at the T567 to increased metastatic potential in HCC and osteosarcoma in 
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vivo [85, 110]. Western blot analysis of orthotopically implanted CRC primary tumor and 
corresponding liver metastasis tissue lysates showed an increased ezrin expression and its 
phosphorylation at T567 site in liver metastasis compared to the primary tumor (Figure 3A). 
Fehon et al. (2010) have shown that following ezrin activation through phosphorylation at the 
T567 site, ezrin translocates to the plasma membrane and binds to various membrane or adaptor 
proteins[89]. Quantification of IHC staining of GEO orthotopically implanted tumors showed 
increased expression of p-ezrin T567 in liver metastasis compared to the primary colonic tumor 
(Figure 3B and C). Moreover, specific membrane staining was observed in the liver metastasis 
confirming ezrin translocation to the plasma membrane after activation through phosphorylation 
at T567. Orthotopic implantation was also performed with the IGF1R-dependent CBS CRC cell 
lines [16, 152, 187] to generate primary colonic tumor and liver metastasis (Figure 3D). We 
observed an increased expression of p-ezrin T567 in the CBS liver metastasis as well (Figure 3E). 
             Previously, we have shown that reconstitution of TGFβ signaling blocks metastasis in 
subsets of IGF1R-dependent CRC with attenuated TGFβ receptors by increasing its TGFβ tumor 
suppressor activity [16, 180]. GEO cells with attenuated TGFβ type I receptor (TGFβRI) are 
highly metastatic. Restoration of TGFβRI in the GEO cells (cell line termed as GEORI) was 
observed to be poorly metastatic with functional TGFβ tumor suppressor signaling [16, 180]. 
Increased ezrin and p-ezrin T567 expression was observed in the highly metastatic GEO cells 
compared to the poorly metastatic GEORI cells with functional TGFβ tumor suppressor signaling 
(Figure 3F). 
             Increased expression of ezrin and p-ezrin T567 was further confirmed in another set of 
orthotopically implanted GEO CRC primary tumor and liver metastasis tissue lysates (Figure 4A 
and B). Similar results were obtained comparing HCT116 and HCT116b cells, which are 
isoclonal variants isolated from the same patient’s primary colon carcinoma in our laboratory 
[181, 189]. Both HCT116 and HCT116b show 100% primary tumor invasion but vary 
significantly in their metastatic capabilities [181, 189, 190]. HCT116 cells are highly metastatic 
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compared to HCT116b [181, 189, 190]. We observed that HCT116 cells demonstrated increased 
ezrin and p-ezrin T567 expression compared with HCT116b cells (Figure 4C). Moreover, IHC of 
the orthotopically implanted HCT116 CRC tumors showed increased expression of p-ezrin T567 
in liver metastasis compared to the primary tumor (Figure 4D). These results confirmed the 
increased expression of p-ezrin T567 in CRC liver metastasis. Interestingly, as reported earlier 
that ezrin activation requires PIP2 binding and phosphorylation, we observed an increased 
expression of PIP2 in liver metastasis compared to primary tumors by IHC and western blot 
studies (Figure 4E and F). 
3.4.3.    Bioinformatics analysis of ezrin in colorectal cancer metastatic signaling 
Clarke et al. (2003) profiled the gene expression signature of CRC patient tumors in response to 
chemotherapy [191]. Thirty five human CRC samples were compared with normal colon samples 
in the study [191]. Using Oncomine, an advanced web-based data-mining platform that collates 
HTS cancer-related data [192], we observed approximately 4-fold increase in the ezrin mRNA 
expression in the CRC tumor samples compared with the normal colon samples (Figure S3.1). 
Data mining using Oncomine also revealed transcriptional upregulation of ezrin in advanced 
stages of breast, pancreatic and prostate cancer patient specimens (data not shown). We utilized 
the Ingenuity Pathways Analysis (IPA) tool to generate potential ezrin signaling networks that 
might be involved in colorectal cancer metastasis signaling (Figure 5). Several potential ezrin-
interacting proteins were identified using IPA, including EGF [193], RhoA [76], PIK3CA [81] 
and SRC [87]. All these proteins have been implicated in CRC metastasis. We next performed a 
microarray analysis on the freshly frozen GEO CRC primary colon carcinoma and liver 
metastatic tumor samples to generate transcriptional profiles using the Illumina platform. The 
heat map dendrogram is shown in Figure S3.2A. We observed approximately 4-fold increase in 
the ezrin mRNA expression in liver metastasis compared to the primary tumor (Figure S3.2B and 
Appendix A. Table S3.2). 
3.4.4.    Increased p-ezrin T567 observed in human CRC patient specimens 
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Wang and colleagues reported that ezrin is highly expressed in the CRC compared to the normal 
colon and is correlated with tumor malignancy [179]. We performed and quantified IHC on colon 
TMAs obtained from the National Cancer Institute (NCI) and observed a significant increase in 
ezrin expression in Stage IV CRC when compared to the normal colon (Figure 6A and B). 
Intriguingly, no statistically significant p-ezrin T567 staining was observed between normal colon 
and Stage IV CRC with low overall p-ezrin T567 expression (Figure 6C and data not shown). As 
mentioned earlier, activation of ezrin through phosphorylation at the T567 site leads to its 
translocation to the plasma membrane [76, 81, 194] and has been associated with increased 
metastatic potential [85, 110]. We performed IHC analysis on paired human CRC primary tumor 
(Stage IV) and liver metastasis patient specimens and observed a significant increase in the 
intensity of p-ezrin T567 staining in the liver metastasis compared to the primary tumors (Figure 
6D and E). The increased membrane localization of p-ezrin T567 in human CRC liver specimen 
mimicked the IHC data obtained from the orthotopically implanted GEO tumor specimens, as 
shown in Figure 3B. 
3.4.5.    Ezrin expression is correlated with enhanced metastatic capability 
Bresalier et al. (1987) demonstrated that colon cancer cell lines with progressively increased 
metastatic potential could be developed in which metastases from the parental colon tumor cell 
line were cultured and used as a source of cells for successive cycling [183]. We utilized a similar 
approach to enhance the liver-metastasizing ability of GEO cells by serially passaging liver 
metastases of GEO cell lines. Serial in vivo passaging of metastatic liver tumor from human 
CRC-bearing athymic nude mice was used to generate a highly aggressive cell line after the 6th 
passage, which was termed the GEO Met6 cell line. Increased primary tumor burdens as well as 
the degree of liver metastasis were observed in the GEO Met6 cell line compared to the parental 
GEO cell line (Figure 7A and B). Moreover, GEO Met6 cells demonstrated rapid primary tumor 
growth and about 50% reduction in the number of days to develop distant metastasis compared to 
the parental GEO cell lines (Figure 7C). However, Ki67 staining of liver metastases of parental 
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GEO and GEO Met6 showed no change in the rate of proliferation (data not shown), indicating 
that an increase in tumor burden did not contribute to the enhancement of distant metastasis. 
Importantly, TUNEL staining showed a significant decrease in the cell death in GEO Met6 liver 
metastasis as compared to the parental GEO liver metastasis (Figure 7D and E). We observed an 
increase in the expression of cell survival markers XIAP and survivin in the liver metastases of 
the GEO Met6 cell line compared to the parental GEO control (Figure S3.3A and B). Both XIAP 
and survivin play a critical role in cell survival through caspase inactivation [124] and have been 
newly implicated in metastasis regulation [114]. Our data indicate that the increase in the 
metastatic capability of the GEO Met6 cell line might be partly attributed to the gain of aberrant 
cell survival capabilities and a decrease in cell death signaling. Furthermore, western blot and 
IHC analysis of GEO Met6 primary and liver metastasis tissue lysates showed a higher 
expression of ezrin in the GEO Met6 metastatic liver tumor (Figure 7F and Figure S3.3C). 
3.4.6.    Cell survival regulation by ezrin in CRC cells 
It has been shown that Akt and its downstream signaling components are critical for aberrant cell 
survival in CRC [11, 166]. Recently, ezrin has been linked to Akt-mediated cell survival [81, 
195]. It was reported that Akt2 specifically activated ezrin at the T567 phosphorylation site 
[195].We observed an increased expression of Akt2 in the liver metastatic tumors compared to 
primary colonic tumors in the GEO orthotopic tumors (Figure S3.4). Akt phosphorylates XIAP at 
the S87 site and reduces its degradation, conferring resistance to caspase activation and apoptosis 
[151]. Dohi et al. (2007) have demonstrated that under conditions of stress, survivin forms a 
complex with XIAP in the cytosol, leading to XIAP stabilization and prevention of its 
proteasomal degradation by suppressing its E3-ubiquitin ligase activity [124]. The survivin/XIAP 
complex has been shown to be a critical cell survival mechanism for tumor growth in vivo and for 
supporting the metastatic process in vivo [124]. Transient knockdown (KD) using ezrin siRNA in 
GEO CRC cells led to the downregulation of both XIAP and survivin (Figure 8A). Ezrin KD also 
resulted in approximately 1.5 fold increase in cell death in GEO cells (Figure 8B). Similar results 
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were obtained from ezrin siRNA KD in CBS cells (Figure 8C and D), demonstrating that the 
downregulation of ezrin signaling adversely affect the cell survival capabilities of IGF1R-
dependent GEO and CBS cells. Small molecule inhibitors for ezrin (NSC668394 and 
NSC305787) have been recently identified as potential drug candidates. Bulut et al. (2012) 
showed that both of these drugs directly inhibited ezrin activity at T567, ezrin-actin interaction, 
and ezrin-mediated motility. and that they inhibited lung metastasis of ezrin-sensitive 
osteosarcoma cells following tail-vein injection [82]. We have observed that NSC668394 is 
effective in dephosphorylating ezrin at T567 amino acid and decreases XIAP levels in metastatic 
CRC cells (Figure 8E). Furthermore, NSC668394 was effective in causing cell death as analyzed 
by DNA fragmentation assay (Figure 8F). Similar results were obtained with NSC305787 
treatment in GEO cells (data not shown). Furthermore, we performed the DNA fragmentation 
assay on GEO cells transiently transfected with ezrin T567A/D point mutant constructs and 
observed an increase in cell death with the dominant negative ezrin T567A expression in GEO 
cells. In contrast, ezrin T567D constitutively active ezrin decreased cell death in GEO cells 
(Figure 8G). 
             Based on the effects of ezrin siRNA KD, inhibitor and T567A/D mutant expression on 
IGF1R-dependent CRC cells and also its expression in the orthotopic implanted primary tumors 
and liver metastases of IGF1R dependent GEO CRC cells, we hypothesized that treatment with 
IGF1R inhibitor could downregulate ezrin-mediated cell survival. MK-0646, a novel humanized 
recombinant IGF1R monoclonal antibody and OSI-906, a small molecule tyrosine kinase 
inhibitor, were utilized to inhibit the IGF1R signaling pathway [196]. Both of these drugs are 
currently in clinical trials and showed significant anti-tumor activity [21, 137, 142, 196]. As 
shown in Figure 9A, treatment by MK-0646 of GEO xenografts led to the dephosphorylation of 
p-ezrin T567. However, the total ezrin remained unchanged. Moreover, IHC staining for p-
ezrinT567 showed a decrease in staining intensity in MK-0646-treated GEO xenograft tumors 
compared with the untreated GEO control xenograft (Figure 9B). OSI-906 treatment also resulted 
77 
  
in deactivation of p-ezrinT567 (Figure 9C). Thus, the IGF1R signaling pathway is upstream of 
ezrin and its downstream cell survival signaling. Zhou et al. (2003) demonstrated that PKA can 
phosphorylate ezrin at S66 in gastric parietal cells, which regulate remodeling of the apical 
membrane cytoskeleton associated with acid secretion in parietal cells. However, to date, no 
functional characterization has been done on PKA-mediated ezrin signaling in cancer. We 
recently demonstrated that PKA can be differentially activated in a cAMP-dependent and -
independent manner leading to differential regulation of cell fate in terms of cellular life and 
death [16, 51, 152]. Briefly, IGF1R activation leads to cAMP-dependent PKA activation, leading 
to increased XIAP-mediated cell survival signaling. However, inhibition of IGF1R signaling by 
OSI-906 leads to cAMP-independent PKA activation, resulting in a decrease in XIAP expression 
and increased cell death. For the activation of IGF1R, we used the growth factors Transferrin+ 
Insulin (TI) that has been extensively used to activate the IGF1R signaling [29, 51]. We used 
OSI-906 for inhibition of IGF1R signaling.  
             Due to the commercial unavailability of p-ezrin-S66 antibody, we performed IP studies 
using ezrin antibody and immunoblotted for phospho-Serine in GEO cells under conditions of 
cAMP-dependent and -independent PKA activation. We report the new finding that IGF1R 
inhibition abrogated serine phosphorylation on ezrin. In contrast, IGF1R activation increased the 
serine phosphorylation on ezrin (Figure 9D). We constructed dominant negative S66A and 
constitutive active S66D ezrin mutant constructs as demonstrated in the original work by Zhao et 
al. [96]. We observed that ezrin S66A/D mutants differentially regulate CRC cells with regard to 
XIAP and survivin expression and control of cell survival (Figure 9E and F). 
3.5.    Discussion 
CRC is the second most common cause of cancer-related death in United States [197]. Early 
stages of CRC are controlled by surgical resection followed by adjuvant chemotherapy; however, 
therapies directed at disseminated disease (which is the main cause of death) are less effective 
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[11]. Therefore, identifying novel biomarkers for the development of anti-metastatic therapeutic 
strategies is a pressing need. Overexpression of IGF1R signaling components is common to 
several types of cancer [29, 159]. CRC is one of the most prevalent cancers in which IGF1R 
signaling components have been linked to cancer progression [29, 127, 159]. Dependence of 
malignant properties of CRC cells on IGF1R signaling has also been demonstrated and several 
IGF1R inhibitors are in clinical trials [16, 29]. IGF1R signaling exerts its anti-apoptotic effect 
through the activation of the IRS1/IRS2/PI3K/Akt pathway [26, 148, 149]. IGF1R-dependent 
GEO and CBS cell lines were used in this study to generate primary and liver metastatic tumors 
by an orthotopic mouse metastasis model system developed in our laboratory that reflects the 
metastatic pattern of human CRC and has been used extensively to characterize several potential 
molecular targets associated with CRC metastasis [12, 14-16, 175, 189, 190]. 
             A 2D-DIGE/MALDI–TOF proteomic approach was used to identify the differences in 
global protein expression between GEO primary colonic tumors and corresponding liver 
metastases. Using this approach, we identified that ezrin, a member of the ERM protein family 
[64, 66], was highly expressed in liver metastasis when compared to the primary colonic tumor. 
In the recent report by Sugihara et al. [171], proteomic characterization of 59 paired normal 
colorectal epithelial and tumor tissues was performed using 2D-DIGE. While the authors 
characterized the APC-binding protein EB1 as a candidate biomarker and therapeutic target, 
Ezrin was also shown to be upregulated by 2.5 fold in the tumor tissues compared to normal 
tissues. Western blot analysis also confirmed an increased expression of ezrin in several paired 
tumor tissues compared to their corresponding normal epithelial tissues. However, ezrin was not 
further investigated by Sugihara and colleagues. 
             Ezrin belongs to the ezrin–radixin–moesin (ERM) family of proteins which share 
approximately 75% sequence homology [64, 66] and was first characterized as a component of 
intestinal brush border microvilli [67]. Ezrin acts as a linker between the plasma membrane and 
the actin cytoskeleton [76, 81, 90] and is present in the cytoplasm in an inactive dormant, closed 
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conformation, where the NH2-terminal domain is tightly bound to the COOH-terminal domain, 
masking several of its protein-binding sites, including the F-actin binding site [77, 90, 194]. The 
activation of ezrin is mediated by binding of its NH2-terminal domain to the phosphatidylinositol 
4,5-biphosphate (PIP2) and phosphorylation of a conserved T567 site in the COOH-terminal 
domain [88, 89]. Phosphorylation at T567 leads to the dissociation of the two binding domains of 
ezrin, changing its inactive closed conformation to an open activated form and thereby exposing 
several protein binding sites [89, 90, 194]. Once activated through phosphorylation at T567, ezrin 
is translocated to the plasma membrane where it binds to various membrane proteins such as 
CD44/43, ICAM2/3 either directly or through adaptor proteins such as NHERF1/2 with the NH2-
terminal domain, and to actin with the COOH terminal domain [89] allowing ezrin to function as 
plasma membrane actin filament cross-linkers [76, 81, 194]. Ezrin phosphorylation at T567 was 
correlated with hepatocellular carcinoma (HCC) and osteosarcoma metastases in vivo [85, 110]. 
Chen et al. (2011) demonstrated the involvement of p-ezrinT567 during HCC intrahepatic 
metastasis [85]. Ren et al. (2009) showed that ezrin phosphorylation at T567 is dynamically 
regulated during osteosarcoma metastatic progression [110]. Despite the earlier reports on the 
increased ezrin expression with CRC progression [83, 179], a direct link of activated ezrin at 
T567 with CRC cell survival and metastasis has not been investigated. 
             We report increased p-ezrin T567 in liver metastases compared to the primary colonic 
tumors in the IGF1R-dependent GEO and CBS orthotopically implanted CRC tumors. Moreover, 
IHC analysis demonstrated a differential pattern of staining with increased membrane staining of 
p-ezrin T567 in liver metastases compared to primary colonic tumors. Correlative studies using 
human CRC primary and liver metastatic specimens showed a similar membrane-staining pattern 
of liver metastases. We made the striking observation by colon TMA studies that ezrin and not p-
ezrin T567 was significantly increased in Stage IV CRC patient specimens compared to normal 
colon tissues. A possible reason might be attributed to the low PIP2 activity in primary colon 
tumors but a high activity in liver metastasis. As PIP2 binding and activation is required for ezrin 
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activation at T567, a high expression of PIP2 specifically in the liver metastasis might serve as a 
critical factor in increased ezrin T567 phosphorylation specifically in the metastatic stage. The 
demonstration of increased p-ezrin T567 in highly metastatic GEO and HCT116 cell lines as 
compared to the poorly metastatic GEORI and HCT116b cell lines might be due to its metastasis-
specific function, which is yet to be determined. Additionally, we made the novel observation by 
ezrin siRNA, inhibitor and T567A/D point mutant studies that ezrin regulates cell survival by 
modulating IAPs survivin and XIAP, which have been implicated in metastasis. Furthermore, we 
reported the novel finding that PKA phosphorylates ezrin at S66 that in turn increased XIAP and 
survivin expression and decreased cell death. These IAPs were also observed to be upregulated in 
the liver metastasis tumors arising from the enhanced liver-metastasizing GEOMet6 cells. 
Moreover, IGF1R antagonists (MK-0646 and OSI-906) downregulated ezrin activation at T567, 
indicating for the first time that ezrin signaling is downstream of IGF1R signaling. 
3.6.    Conclusion 
We have demonstrated the increased expression of p-ezrin T567 in liver metastasis in both 
orthotopic implantation studies in vivo and in IHC studies of human CRC patient specimens. 
Furthermore, we showed for the first time that p-ezrin T567 is regulated by the IGF1R signaling 
pathway and this activation enhances cell survival in CRC cells by modulating XIAP and 
survivin. Thus, p-ezrin T567 may be a potential biomarker as well as a target for anti-metastatic 
therapy. Further in vitro and in vivo preclinical studies are required to determine the role of p-
ezrin T567 in the development and/or maintenance of established metastasis in solid tumors 
including CRC. The findings in this study have the potential to open new avenues of research into 
the molecular mechanisms of CRC metastasis and the development of novel anti-metastatic 
therapeutic strategies for human CRC. 




Figure 3.1.  Proteomic analysis identifies ezrin upregulation in CRC liver metastasis: (A) 
IGF1R dependent GEO cells were used to generate primary colon and liver metastatic tumors by 
orthotopic implantation techniques as described in the Materials and Methods section. These 
tumor tissues were further utilized for the proteomics analysis. (B) 2D-DIGE image showing 
differential protein expression between primary colon tumor and liver metastases. The primary 
colon and liver metastatic tumor tissue lysates were labeled with Cy3 (green) and Cy5 (red) 
fluorescent dyes respectively. The images of the cy3 and cy5 labeled primary and liver metastatic 
tumor protein samples are generated by laser scanning. The white circle depicts protein spot 
number 2. (C) The individual primary tumor and liver metastasis gel images and merged image of 
protein spot number 2 show greater intensity in the liver metastatic tumor lysate. (D) The 3D-
peak view of protein spot number 2 in primary and liver metastatic tumors analyzed by the 




















Figure 3.2.  The individual 2D-DIGE gel images of GEO primary colon carcinoma and liver 


































Figure 3.3.  Elevated levels of p-ezrin T567 in liver metastasis: (A) Western blot analysis 
comparing GEO primary colon and liver metastatic tumors showing increased ezrin and p-ezrin 
T567 protein expression in the liver metastasis. (B) IHC analysis of the GEO primary colon and 
liver metastatic tumors showing increased p-ezrin T567 staining in the liver metastasis. The 
increased expression of p-ezrin T567 is localized to the membrane region as demonstrated by its 
ring-like appearance on the liver metastatic cells. (C) Densitometry analysis of the IHC images of 
GEO primary tumors and liver metastasis by Image J followed by statistical analysis showing an 
increased expression of p-ezrin T567 in liver metastasis specimen. (D) IGF1R-dependent CBS 
cells were used to generate primary colon and liver metastatic tumors by orthotopic implantation 
techniques as described in the Materials and Methods section. These tumor tissues were further 
utilized for the western blot analysis. (E) Western blot analysis comparing CBS primary colon 
and liver metastatic tumors showing increased p-ezrin T567 protein expression in the liver 
metastasis. (F) Highly metastatic GEO cells that lack functional TGFβ tumor suppressor signaling 
show high ezrin and p-ezrin T567 expression in vitro. In contrast, poorly metastatic GEORI cells 
stably transfected with TGFβ Receptor Type I (TGFβRI) to restore functional TGFβ tumor 





















Figure 3.4.  Increased levels of p-ezrin T567 in CRC liver metastasis: (A) Another set of 
IGF1R-dependent GEO cells were used to generate primary colon and liver metastatic tumors by 
orthotopic implantation techniques as described in the Materials and Methods section. These 
tumor tissues were further utilized for the western blot analysis. (B) Western blot analysis 
comparing GEO primary colon and liver metastatic tumors showing increased p-ezrin T567 
protein expression in the liver metastasis. (C) Western blot analysis comparing highly metastatic 
HCT116 and poorly metastatic iso-clonal variant HCT116b cells showing increased p-ezrin T567 
in the HCT116 cells. (D) IHC analysis of the HCT116 primary colon and liver metastatic tumors 
showing increased p-ezrin T567 staining in the liver metastasis. (E, F) IHC and western blot 
analysis of the GEO primary colon and liver metastatic tumors showing increased PIP2 staining 
























Figure 3.5.  Ezrin network in colorectal cancer metastatic signaling: The intuitive web-based 
analytical tool Ingenuity Pathway Analysis (IPA) was used to generate plausible colorectal cancer 





















Figure 3.6.  IHC studies on ezrin and p-ezrin T567 in human CRC patient specimens: (A) 
NCI colon tissue microarray (colon TMA) analysis of ezrin in normal colon and stage IV primary 
colon carcinoma obtained from CRC patient specimens. (B) Densitometry analysis of the IHC 
images of colon TMA comparing normal colon and stage IV primary colon carcinoma by Image J 
followed by statistical analysis showing an increased expression of ezrin in stage IV colon 
carcinoma specimen. (C) IHC staining of p-ezrin T567 in colon TMAs showing negligible 
staining in both normal colon and stage IV colon carcinoma specimen. (D) IHC analysis of the 
human CRC stage IV colon carcinoma and liver metastatic tumors obtained from the same patient 
showing increased p-ezrin T567 staining in the liver metastasis. Similar to the p-ezrin T567 
staining in the GEO orthotopically implanted liver metastatic tumors, the increased p-ezrin T567 
is preferentially localized to the cellular membrane region on the liver metastatic cells. (E) 
Densitometry analysis of the IHC images of the human CRC stage IV colon carcinoma and liver 
metastatic tumors obtained from the same patient by Image J followed by statistical analysis 


















Figure 3.7.  Ezrin expression is correlated with enhanced liver metastasizing ability: (A) 
IGF1R-dependent GEO Met6 cells were generated by serial passaging of the liver metastatic 
tumor tissues as discussed in the Materials and Methods section. Comparison of the 
orthotopically implanted GEO cells (mentioned here as GEO Control) and GEO Met6 cells 
showed remarkable differences in their tumor formation. (B) GEO Control and GEO Met6 
primary colonic and liver metastatic tumor images. (C) Comparison of the approximate number 
of days needed to develop liver metastasis in the GEO and GEO Met6 xenograft-implanted 
animals. (D) TUNEL assay of GEO and GEO Met6 liver metastatic tumor tissues showing a 
significant decrease in cell death in the GEO Met6 liver metastatic tumor tissues as observed by 
reduction in TUNEL staining. (E) Densitometry analysis of the TUNEL staining of GEO and 
GEO Met6 liver metastatic tumor tissues by Image J followed by statistical analysis showing a 
decrease in TUNEL staining in the GEO Met6 liver metastasis specimen. (F) Western blot 
analysis showing a significant increase in ezrin protein expression in the GEO Met6 liver 













Figure 3.8.  Ezrin regulates aberrant cell survival in CRC cells: (A) Ezrin siRNA knockdown 
in GEO cells (termed as GEO ezrin siRNA) shows a reduction in the inhibitor of apoptosis (IAP) 
family proteins XIAP and survivin. (B) DNA fragmentation assay of GEO and GEO ezrin siRNA 
cells showing significant increase in cell death in vitro. (C) Ezrin siRNA knockdown in CBS cells 
(termed as CBS ezrin siRNA) shows a reduction in XIAP and survivin expression. (D) DNA 
fragmentation assay of CBS and CBS ezrin siRNA cells showing significant increase in cell death 
in vitro. (E) Ezrin inhibitor NS668394 treatment dephosphorylates p-ezrin T567 and decreases 
XIAP expression. (F) NS668394 treatment induces 7.5-fold increase in cell death in GEO cells. 
(G) DNA fragmentation assay showing increased cell death with ezrin T567A mutation compared 


























Figure 3.9.  Regulation of p-ezrin T567 by IGF1R signaling: (A) Inhibition of the IGF1R 
signaling pathway by human recombinant monoclonal antibody MK-0646 in athymic mice 
IGF1R-dependent GEO xenograft lead to inhibition of p-ezrin T567. However, the total ezrin 
protein remained unchanged. (B) IHC analysis of GEO control and MK-0646-treated xenograft 
showing a decrease in staining intensity of p-ezrin T567 in the MK-0646-treated xenograft. (C) 
Treatment of IGF1R-kinase inhibitor OSI-906 on GEO cells in vitro leads to loss of ezrin 
phosphorylation at T567 site without change in total ezrin. (D) Ezrin IP studies showing decrease 
in p-Serine following IGF1R inhibition by OSI-906 and increase following IGF1R activation for 
1 hour (E) Ezrin IP following site-directed mutagenesis showing decrease in p-Serine in dominant 
negative ezrin S66A expressing GEO cells. In contrast, constitutive active ezrin S66D expression 
increases p-Serine on ezrin IP pull down. Ezrin S66A/D mutation also shows loss of XIAP and 
survivin with S66A and increase with S66D ezrin mutation. (F) Increased cell death observed 
























Figure S3.1. Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and 
visualization of ezrin mRNA expression in human colorectal carcinoma showing approximately 
4-fold increase compared to normal colon. The original study on the development of Oncomine™ 








































Figure S3.2. Microarray analysis: Microarray analysis of GEO primary colon and liver 
metastatic tumors showed approximately 3-fold increase in ezrin mRNA expression in CRC liver 

































Figure S3.3: Enhancement of liver metastasizing ability leads to cell survival: Western blot 
analyses showing an increased expression of (A) XIAP and (B) survivin in GEO Met6 liver 
metastatic tumors compared to the liver metastatic tumors originating from the GEO cells (termed 
here as GEO Control). (C) IHC analysis of the GEO Met6 primary colon and liver metastatic 





























Figure S3.4. Elevated levels of Akt2 in liver metastasis: Western blot analysis showing an 
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4.   TGFβ and IGF1R signaling activate protein kinase A through differential  
       regulation of ezrin phosphorylation in colon cancer 
4.1.    Abstract 
Aberrant cell survival plays a critical role in cancer progression and metastasis. We have 
previously shown that ezrin, a cAMP dependent A-kinase anchoring protein (AKAP), is 
upregulated in colorectal cancer (CRC) liver metastases. Phosphorylation of ezrin at threonine 
567 (T567) activates ezrin and plays an important role in colon cancer cell survival associated 
with upregulation of XIAP and survivin. In this study, we demonstrate that knockdown of ezrin 
expression or inhibition of ezrin phosphorylation at T567 increases apoptosis through PKA 
activation in a cAMP-independent manner. TGFβ signaling inhibits ezrin phosphorylation in a 
Smad3-dependent and Smad2-independent manner and regulates pro-apoptotic function through 
ezrin-mediated PKA activation. On the other hand, phosphorylation of ezrin at T567 by IGF1R 
signaling leads to cAMP-dependent PKA activation and enhances cell survival. Further studies 
indicate that phosphorylated ezrin forms a complex with PKA RII and dephosphorylated ezrin 
dissociates from the complex and facilitates the association of PKA RII with AKAP149, both of 
which activate PKA yet lead to either cell survival or apoptosis.  Thus, our studies reveal a novel 
mechanism of differential PKA activation mediated by TGFβ and IGF1R signaling through 
regulation of ezrin phosphorylation in CRC resulting in different cell fate. This is of significance 
because TGFβ and IGF1R signaling pathways are well characterized tumor suppressor and 
oncogenic pathways respectively with important roles in CRC tumorigenesis and metastasis. Our 
studies indicate that they crosstalk and antagonize each other’s function through regulation of 
ezrin activation. Therefore, ezrin may be a potential therapeutic target in CRC. 
4.2.   Introduction 
Colorectal cancer (CRC) is the third leading cause of cancer related death in the United States. 
Stage I and II cancers that are confined within the wall of the colon are curable by surgical 
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resection; however, the survival rate of cancer patients is drastically reduced when cancer 
metastasizes to distant organ sites such as liver and/or lungs [11, 198]. Despite significant 
improvements in early diagnosis and treatment of CRC, metastasis and recurrence of the disease 
remain the main cause of cancer death [5, 8, 11]. Genetic and epigenetic changes pivotal for 
metastasis are acquired at late stages of CRC during progression to advanced disease [11]. 
Therefore, identification of these changes and understanding the underlying mechanisms are 
critical for the development of novel anti-metastatic therapies. 
             Our recent studies have demonstrated that expression of ezrin is upregulated in CRC liver 
metastases when compared to primary tumors in an orthotopic model of colon cancer [199]. 
Ezrin, a member of the ezrin-radixin-moesin (ERM) family [64, 66, 69, 200], exists in two 
conformations, an active open form mainly localized at the plasma membrane and a dormant 
closed form largely resides in the cytoplasm. Inactive ezrin forms oligomers where the C-terminal 
domain folds back and binds tightly to the FERM domain, masking several of its active sites [79, 
194, 200]. Phosphorylation at threonine 567 (T567) transitions ezrin from inactive oligomers into 
active monomers by unmasking the active sites through dissociation of FERM and C-terminal 
domains [88-90, 194, 201]. Ezrin plays an important role in cell motility and invasion and has 
been implicated in metastasis of several types of cancer including CRC [83, 85, 107, 108, 110, 
179]. In addition, ezrin plays a key role in cell survival of colon cancer cells and regulates 
expression of Inhibitor of Apoptosis Proteins (IAP), XIAP and survivin, which have been shown 
to be involved in cell survival and metastasis [114, 199]. We have previously shown that IGF1R 
signaling regulates ezrin phosphorylation at T567 [199]. Other studies have shown that ezrin is a 
downstream effector of the PI3K/Akt pathway [195, 202]. Nevertheless, little is known of the 
mechanism of ezrin-mediated cell survival.  
            Dransfield et al. characterized ezrin as a cyclic AMP (cAMP)-dependent A-kinase 
anchoring protein (AKAP) [103]. There are more than 50 AKAPs identified. Protein kinase A 
(PKA) consists of catalytic subunits and inhibitory regulatory subunits and plays a dominant role 
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in the integration of multiple signal transduction networks [203]. AKAPs interact with the 
regulatory subunits of PKA and target these supramolecular complexes to specific subcellular 
localizations, where they regulate phosphorylation of specific substrates and execute different 
functions [47, 204]. For example, AKAP149/PKA contributes to the disruption of the 
XIAP/survivin complex through phosphorylation of survivin at serine 20, leading to proteasome-
mediated degradation of XIAP [16, 124].  
            In this study, we demonstrate that knockdown of ezrin expression or inhibition of ezrin 
phosphorylation in GEO and FET cells increases apoptosis through activation of PKA in a 
cAMP-independent manner. AKAP149 plays an important role in this process. In addition, we 
show that TGFβ inhibits ezrin phosphorylation at T567 in a Smad2-independent and Smad3-
dependent manner, resulting in PKA activation and induction of apoptosis.  On the other hand, 
phosphorylation of ezrin at T567 by IGF1R signaling leads to cAMP-dependent PKA activation 
and increased cell survival. Further studies indicate that phosphorylated ezrin displays more 
association with PKA RII than dephosphorylated ezrin; hypophosphorylation of ezrin facilitates 
complex formation of PKA RII and AKAP149 whereas hyperphosphorylation of ezrin reduces 
their association. Therefore, our studies uncover a novel mechanism of differential activation of 
PKA mediated by TGFβ and IGF1R signaling through regulation of the phosphorylation status of 
ezrin, which leads to different cell fates. Given the importance of TGFβ and IGF1R signaling in 
CRC, it implicates that ezrin may be a potential therapeutic target in CRC.  
4.3.    Materials and Methods 
4.3.1. Cell lines 
GEO, FET and CBS CRC cell lines were originally developed from primary CRC tumors and 
have been extensively characterized and validated in our laboratory [143, 181]. Cells were 
maintained at 37C in a humidified atmosphere, using chemically defined serum-free medium 
consisting of McCoy’s 5A medium (Sigma-Aldrich) supplemented with amino acids, pyruvate, 
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vitamins, antibiotics, and growth factors transferrin (4μg/ml; Sigma-Aldrich), insulin (20μg/ml; 
Sigma-Aldrich), and EGF (10ng/ml; R&D Systems). Supplemented McCoy’s medium (“SM”) is 
McCoy’s 5A medium supplemented with antibiotics and nutrients but lacking growth factors. 
Cells were routinely sub-cultured with 0.25% trypsin (Invitrogen) in Joklik’s medium 
(Invitrogen) containing 0.1% EDTA. 
4.3.2. Antibodies 
The following primary antibodies were obtained from Cell Signaling Technology (Danvers, MA): 
Survivin rabbit polyclonal antibody (catalog#2803), XIAP rabbit monoclonal antibody 
(catalog#2045), AKAP149 rabbit monoclonal antibody (catalog#5203), PKACatα rabbit 
monoclonal antibody (catalog#5842), TGFβRI rabbit polyclonal antibody (catalog#3712), Smad2 
rabbit monoclonal antibody (catalog#3122), Smad3 rabbit monoclonal antibody (catalog#9523), 
p-Smad3 rabbit monoclonal antibody (catalog#9520), CREB rabbit monoclonal antibody 
(catalog#9197),  p-CREB rabbit monoclonal antibody (catalog#9198) and Caspase 7 rabbit 
polyclonal antibody (catalog#9492). Ezrin mouse monoclonal antibody (catalog#sc-71082) and 
TGFβRII mouse monoclonal antibody (catalog#sc-17791) were obtained from Santa Cruz 
Biotechnology (Dallas, TX). P-ezrinT567 rabbit polyclonal antibody (catalog#ab47293) and 
PKARII mouse monoclonal antibody (catalog#ab124400) were obtained from Abcam 
(Cambridge, MA). Actin rabbit antibody (catalog#A2066) was obtained from Sigma-Aldrich (St. 
Louis, MO).   
4.3.3. Pharmacological antagonists 
Ezrin small molecule inhibitor NSC668394 (NSC) was purchased from Millipore. TGFβ1 was 
purchased from R&D Systems. PKA inhibitor H89 (catalog#9844) and forskolin (catalog#3828) 
were obtained from Cell Signaling Technology. Pan-AKAP inhibitor Ht31 (catalog#V8211) was 
obtained from Promega 
4.3.4. Transfection studies 
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Ezrin GIPZ lentiviral shRNAs and on-TARGETplus SMARTpool AKAP149 siRNA were 
purchased from Dharmacon (Thermo Fisher Scientific Inc., USA) and knockdowns were 
performed according to the manufacturer protocols. Smad2, Smad3 and PKACatα shRNAs were 
obtained from Santa Cruz Biotechnology and knockdowns were performed as described 
previously [16, 205]. Ezrin wild type (WT), T567A9 (phospho-deficient) and T567D (phospho-
mimetic) mutants were kindly provided by the Khanna Laboratory, NIH [110]. 
4.3.5. Cell lysate preparation 
GEO, FET and CBS cells were harvested at 70-80% confluency. Cells were washed in cold 5% 
PBS and collected in lysis buffer [50mmol/L Tris (pH 7.4), 100 mmol/L NaCl, 1% NP40, 2 
mmol/L EDTA, 0.1% SDS, 50 mmol/L NaF, 10 mmol/L Na₃VO₄, 1 mmol/L 
phenylmethylsulfonyl fluoride, 25 μg/ml β-glycerophosphate, and one protease inhibitor cocktail 
tablet from Roche]. Crude cell lysates were homogenized using a 21 gauge needle to shear DNA 
and lysed for 30 minutes on ice at 4 ̊C. Cell lysates were then cleared by centrifugation at 13000 
rpm for 20 minutes at 4 ̊C. Protein concentrations were determined by the Pierce bicinchoninic 
acid protein assay (Pierce Biotechnology).  
4.3.6. Western Blotting and Immunoprecipitation   
rotein (30-100µg) was fractionated by SDS-PAGE and transferred onto a nitrocellulose 
membrane (Amersham Biosciences) by electroblotting. The membrane was blocked with 5% 
nonfat dry milk in 1X TBST (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween20) for 1 hour at 
room temperature or overnight at 4C. The membrane was then incubated in primary antibodies 
for 1½ hour at room temperature or overnight at 4C with 5% nonfat dry milk in 1X TBST or 5% 
bovine serum albumin (BSA) in 1X TBST according to the antibody manufacturer’s directions. 
The membrane was washed three times with 1X TBST for 10 minutes each and incubated with 
horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) for 1 hour at 
room temperature. This was followed by washing in 1X TBST and proteins were detected by 
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enhanced chemiluminescence system (Amersham Biosciences). Immunoprecipitation was 
performed with 500 µg protein aliquots using magnetic beads (Millipore) according to the 
manufacturer’s instructions. 
4.3.7. Apoptosis Assay 
Apoptosis was measured by the Cell Death Detection ELISA Plus kit (Roche) as described 
previously [188]. Inhibition of cell proliferation was assessed by the MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as described previously [180, 
188]. 
4.3.8. PKA activity assay 
PKA activity was measured using the PepTag nonradioactive protein kinase assay kit from 
Promega (catalogue#V5340) using kemptide (LRRASLG) in the absence of cAMP according to 
the manufacturer’s protocol as described previously [16]. 
4.3.9. Cyclic AMP activity assay 
For quantitative determination of cAMP, a non-radioactive Direct Cyclic AMP Enzyme 
Immunoassay kit from Enzo Life Sciences (catalogue#ADI-901-066) was utilized and the assay 
was performed according to the manufacturer’s protocol as described previously [16].  
4.3.10.Statistical analysis  
Statistical significance was determined using one-way ANOVA analysis and student t-test with a 
p value less than 0.05 using the Graphpad Prism 7 software. All the experiments were repeated 
three times independently, for the ANOVA analysis. The results were expressed as mean  SE for 
each treatment.           
4.4.    Results 
4.4.1. Knockdown of ezrin expression activates PKA and induces apoptosis in colon cancer 
cells. Recently, we demonstrated that transient knockdown of ezrin using siRNA leads to 
downregulation of XIAP and survivin expression [199]. To understand the underlying molecular 
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mechanism, stable knockdown (KD) of ezrin expression was performed using GIFZ lentiviral 
shRNA#1 and #3 in GEO and FET colon cancer cells. A non-targeting shRNA (NT sh) was used 
as a control. Ezrin expression was significantly reduced by ezrin shRNAs in both cell lines 
(Figure 1A). As a result, DNA fragmentation assays showed an approximately 2-fold increase in 
apoptosis in ezrin KD cells when compared to the NT sh control cells (Figure 1B). In addition, 
cleaved caspase 7 was higher in ezrin KD cells than in NT sh cells (Figure 1C), confirming the 
results of DNA fragmentation assays. Expression of XIAP and survivin was downregulated in 
both GEO and FET cells (Figure1 C). These results indicated that inhibition of ezrin expression 
leads to increased apoptosis associated with reduced XIAP and survivin expression in colon 
cancer cells. PKA activation has been shown to disrupt XIAP/survivin complex formation, 
leading to degradation of XIAP and survivin and induction of apoptosis [16]. We next determined 
whether ezrin KD had any effect on PKA activity. PKA activity assays showed that ezrin KD 
increased PKA activation by 2-3 fold relative to NT sh control (Figure 1D). Phosphorylation of 
CREB, a direct target of PKA [206], was increased in ezrin KD cells, and pretreatment with H89, 
a specific PKA inhibitor which binds to the PKA catalytic α subunit to inhibit its activation, 
completely abrogated ezrin KD-mediated increase in CREB phosphorylation (Figure 1E), 
supporting the ability of ezrin KD to activate PKA. Further studies showed that ezrin KD 
dissociated PKA catalytic subunit α (PKACatα) from its inhibitory regulatory subunit RII (Fig. 
1F). Since cAMP binds to the PKA regulatory subunits and dissociates them from the catalytic 
subunits to activate PKA [16, 124], we next determined whether ezrin KD increased cAMP 
production. cAMP levels were measured using a non-radioactive cAMP enzyme immunoassay. 
Forskolin, a PKA activator, was used as a positive control.  Treatment of forskolin led to a 
significant increase in cAMP levels (Figure 1G). In contrast, ezrin KD was unable to increase 
cAMP production in both GEO and FET cells (Figure 1G). These results indicate that ezrin KD 
activates PKA in a cAMP-independent manner.  
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             To determine whether ezrin KD induces apoptosis through PKA activation, expression of 
the PKA catalytic α subunit was knocked down by a shRNA in FET cells (designated PKACatα 
KD) (Figure 2A). As expected, PKACatα KD markedly reduced endogenous PKA activity and 
blocked ezrin KD-induced PKA activation (Figure 2B). There was no difference in ezrin 
phosphorylation at T567 and expression of total ezrin between PKACatα KD and scrambled 
shRNA control cells (Figure 2A). Although knockdown of PKACatα did not affect XIAP and 
survivin expression (Figure 2A), it blocked ezrin KD-mediated downregulation of XIAP and 
survivin expression (Figure 2C) Consequently, PKACatα KD did not induce apoptosis, but 
blocked apoptosis induced by ezrin KD (Figure 2D). These results demonstrated that ezrin KD 
mediates apoptosis through PKA activation.        
4.4.2. Inhibition of ezrin phosphorylation at T567 leads to PKA activation and induction of 
apoptosis. Ezrin is present in an inactive and closed conformation in the cytoplasm and 
phosphorylation at T567 activates ezrin [194]. Previously, we have shown that ezrin is 
hyperphosphorylated at T567 in CRC liver metastasis when compared to primary tumors [199]. 
We, therefore, hypothesized that inhibition of ezrin phosphorylation at T567 would inactivate 
ezrin, leading to PKA activation and induction of apoptosis. To test this hypothesis, site directed 
mutagenesis was performed. An ezrin phosho-deficient mutant (designated as T567A), in which 
threonine 567 was replaced by alanine, was generated. GFP-tagged Ezrin T567A was introduced 
into ezrin KD cells and GFP-tagged wild type ezrin (designated as WT) was used as a control 
(Figure 3A). Expression of ezrin T567A led to downregulation of XIAP and survivin expression 
(Figure 3A), increased apoptosis (Figure 3A & 3B) and enhanced PKA activation (Figure 3C), 
whereas restoration of WT ezrin increased XIAP and survivin expression (Figure 3A), decreased 
apoptosis (Figure 3A & 3B) and reduced PKA activation (Figure 3C) to levels observed in 
control cells. Ezrin T567A-mediated PKA activation was independent of cAMP since cAMP 
levels remained unchanged in Ezrin T567A- or WT ezrin-expressing cells (Figure 3D). These 
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results indicate that inhibition of ezrin phosphorylation at T567 activates PKA and induces 
apoptosis in colon cancer cells. 
            We next determined the effects of NSC668394 (designated as NSC), a small molecule 
inhibitor which inhibits ezrin phosphorylation at T567 [82], on PKA activation and apoptosis of 
colon cancer cells. Treatment of GEO and FET cells with increasing concentrations of NSC 
showed a dose-dependent inhibition of ezrin phosphorylation at T567, with no change in the 
levels of total ezrin (Figures 4A). Expression of XIAP and survivin was downregulated by NSC 
in a dose-dependent manner (Figure 4A). In addition, a 2 to 4- and 3 to 5- fold increase in 
apoptosis was observed after NSC treatment for 2 and 6 hours respectively (Figure 4B). 
Moreover, PKA activity assays showed a significant time-dependent activation of PKA by NSC 
treatment in GEO and FET cells, which was abrogated by pretreatment with H89 (Figure 4C). 
Forskolin was included as a positive control (Figure 4C). NSC also activated PKA in CBS colon 
cancer cells (Figure S1). As expected, NSC-mediated PKA activation was independent of cAMP 
(Figure 4D). These results indicate that inhibition of phosphorylation of ezrin at T567 by NSC 
activates PKA and induces apoptosis in colon cancer cells.  Importantly, knockdown of the PKA 
catalytic α subunit in FET cells blocked NSC-mediated downregulation of XIAP and survivin 
expression (Figure 4E), prevented NSC-induced apoptosis (Figure 4F) and abrogated NSC-
mediated PKA activation (Figure 4G). These results demonstrate that inhibition of 
phosphorylation of ezrin at T567 by NSC leads to apoptosis through PKA activation.  
4.4.3. TGFβ inhibits ezrin phosphorylation at T567 resulting in PKA activation and 
apoptosis. TGFβ signaling plays an important role in tumorigenesis and metastasis in many 
cancers, including CRC [205]. It has been shown that abrogation of TGFβ signaling promotes cell 
survival under stress and increases metastatic potential of colon cancer cells [145]. We have 
previously shown that TGFβ activates PKA in a cAMP-independent manner leading to apoptosis, 
and that this activation is dependent on Smad3 [16, 51]. TGFβ signaling also downregulates 
XIAP and survivin expression [16]. These results suggest that TGFβ may function through ezrin 
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regulation. We therefore determined whether TGFβ signaling regulates ezrin phosphorylation and 
activation. Treatment of FET cells with TGFβ1 resulted in a time-dependent decrease in ezrin 
phosphorylation at T567 (Figure 5A). To further determine whether TGFβ-mediated inhibition of 
ezrin phosphorylation is Smad-dependent, expression of Smad2 and Smad3 was knocked down 
individually in FET cells by shRNAs specific for Smad2 or Smad3 (Figure 5B). Knockdown of 
Smad2 or Smad3 had little effect on the basal levels of ezrin phosphorylation at T567 (Figure 
5C). However, TGFβ-mediated inhibition of ezrin phosphorylation was prevented in Smad3 
knockdown cells but not in Smad2 knockdown cells (Figure 5C). These results indicate that 
TGFβ inhibits ezrin phosphorylation in a Smad3-dependent and Smad2-independent manner.  
            To demonstrate that TGFβ activates PKA through inhibition of ezrin activation, ezrin 
expression was knocked down in FET cells (Figure 1A). While TGFβ markedly increased PKA 
activity in NT sh control cells, it activated PKA to a much lesser degree in ezrin KD cells (Figure 
5D). Consistently, inhibition of ezrin phosphorylation by NSC treatment attenuated TGFβ-
induced PKA activation (Figure 5E). These results indicate that TGFβ activates PKA at least 
partially through ezrin inhibition.  
Of note, knockdown of ezrin had no effect on expression of TGFβRI and TGFβRII 
(Figure 5F), expression of Smad3 or TGFβ-mediated Smad3 phosphorylation (Figure 5G), 
indicating that ezrin does not affect canonical TGFβ signaling.  
4.4.4. Phosphorylation of ezrin at T567 leads to PKA activation and cell survival. 
We have previously shown that inhibition of IGF1R decreases ezrin phosphorylation at T567 
[199], indicating that IGF1R-mediated signaling activates ezrin by increasing T567 
phosphorylation. Consistently, treatment of GEO cells with transferrin and insulin (TI), which 
activates IGF1R signaling [29], increased ezrin phosphorylation at T567, concurrently with 
increased expression of XIAP and survivin, which was abrogated by ezrin KD (Figure 6A).  
Importantly, TI treatment activated PKA and increased cAMP production (Figure 6B & 6C). 
These results suggest that phosphorylation of ezrin at T567 activates PKA in a cAMP-dependent 
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manner. To determine whether this is the case, an ezrin phosho-mimetic mutant (designated as 
T567D), in which threonine 567 was replaced by aspartic acid, was generated. GFP-tagged ezrin 
T567D was introduced into ezrin KD cells and GFP-tagged WT ezrin was used as a control 
(Figure 6D). Analysis of PKA activity showed that expression of wild type ezrin reversed the 
stimulative effect of ezrin KD on PKA activation whereas expression of ezrin T567D further 
increased PKA activation (Figure 6E) and enhanced production of cAMP (Figure 6F). It indicates 
that, in contrast to ezrin T567A-mediated PKA activation which is cAMP-independent (Figure 
3D), ezrin T567D activates PKA in a cAMP-dependent manner. Moreover, overexpression of 
WT ezrin increased expression of XIAP and survivin (Figure 6D) and prevented apoptosis 
induced by ezrin KD (Figure 6G) whereas overexpression of ezrin T567D not only blocked ezrin 
KD-induced apoptosis but further increased cell survival as compared NT sh control (Figure 6G). 
Taken together, these studies indicate that phosphorylation of ezrin at T567 activates PKA and 
enhances cell survival.  
4.4.5. AKAP149 contributes to ezrin inhibition-mediated PKA activation. 
It has been shown that AKAP/PKA interaction is a prerequisite for targeting PKA and its 
substrate complexes to specific subcellular locations [47]. To determine whether AKAP is 
involved in ezrin inhibition-mediated PKA activation, a pan-AKAP inhibitor Ht31 was utilized. 
Pretreatment with Ht31 abrogated NSC-mediated PKA activation in FET, GEO and CBS colon 
cancer cells (Figure 7A). These results indicate that one or more AKAPs contribute to ezrin 
inhibition-mediated PKA activation. It has been previously shown that TGFβ/Smad3-mediated 
PKA activation is dependent upon AKAP149 [16, 51]. We therefore used siRNA knockdown 
strategies to determine whether AKAP149 is required for PKA activation by ezrin inhibition. 
Knockdown of AKAP149 had little effect on ezrin expression and phosphorylation (Figure 7B, & 
S2A), and ezrin KD did not affect AKAP149 expression (Figure S2B). While AKAP149 KD had 
no effect on XIAP and survivin expression in the control cells, it slightly increased their 
expression in ezrin KD cells (Figure 7B). In addition, AKAP149 KD reduced apoptosis in ezrin 
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KD cells but not in the control cells (Figure 7C). Interestingly, knockdown of AKAP149 did not 
affect PKA activation in the control cells; however, it completely abrogated ezrin inhibition-
mediated PKA activation by NSC (Figure 7D). These results indicate that AKAP149 is essential 
for PKA activation when ezrin activation is inhibited. However, it has little effect on PKA 
activation when ezrin is activated. Given that AKAPs bind the regulatory subunits of PKA (PKA 
RI or PKA RII), leading to the dissociation of regulatory subunits from the catalytic α subunit and 
activation of PKA, and that AKPA149 binds PKA RII [16], we next determined the complex 
formation of PKA RII and AKAP149 by immunoprecipitation (IP) analysis. As shown in Figure 
7E, ezrin KD increased PKA RII/AKAP149 complex formation. While expression of ezrin 
T567A further increased the association of PKA RII and AKAP149, expression of ezrin T567D 
markedly decreased their association (Figure 7E). These results indicate that 
hypophosphorylation of ezrin facilitates complex formation of PKA RII and AKAP149 whereas 
hyperphosphorylation of ezrin prevents their association. It suggests that phosphorylation of ezrin 
enhances the complex formation of ezrin and PKA RII. To investigate whether this is the case, 
PKA RII/ezrin complex formation was determined by IP analysis. The results showed that ezrin 
T567D displays more association with PKARII than ezrin T567A (Figure 7F). These studies 
indicate that phosphorylated ezrin forms a complex with PKA RII and dephosphorylated ezrin 
dissociates from the complex and facilitates the association of PKA RII with AKAP149. 
            Taken together, our studies suggest a novel model of differential activation of PKA 
mediated by the TGFβ/Smad3/AKAP149 or IGF1R/ezrin signaling axis (Figure 8). In the 
presence of TGFβ, TGFβ/Smad3 inhibits ezrin phosphorylation at T567, leading to the 
association of AKAP149 with PKA RII to activate PKA in a cAMP-independent manner, 
suppress XIAP and survivin expression and induce apoptosis. In the context of IGF1R activation, 
ezrin is hyperphosphorylated at T567, which results in the association of ezrin with PKA RII and 
PKA activation. This activation of PKA is cAMP-dependent, increases expression of XIAP and 
survivin and enhances cell survival.  
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4.5.    Discussion 
We have shown in this study that ezrin mediates cell survival through PKA activation. Ezrin 
knockdown or inhibition leads to PKA activation in a cAMP-independent manner and induces 
apoptosis associated with downregulation of XIAP and survivin expression. Further studies 
indicate that PKA activation by ezrin inhibition is dependent upon AKAP149, knockdown of 
which abrogated ezrin inhibition-mediated PKA activation and induction of apoptosis. In 
addition, activation of TGFβ signaling dephosphorylates ezrin at T567 in a Smad3-dependent and 
Smad2-independent manner and TGFβ/Smad3 induces its pro-apoptotic effects through inhibition 
of ezrin phosphorylation. On the other hand, ezrin hyperphosphorylation at T567 mediated by 
IGF1R signaling leads to PKA activation in a cAMP-dependent manner, promoting cell survival 
associated with XIAP and survivin upregulation. These findings suggest that TGFβ and IGF1R 
signaling antagonizes each other by differentially regulating ezrin phosphorylation, which 
activates PKA through different mechanisms and mediates the equilibrium between cell survival 
and apoptosis.  Therefore, PKA signaling plays an important role in the integration of multiple 
signal transduction pathways in colon cancer cells. 
            Previous studies have shown that deregulation of AKAPs contributes to cancer [16, 62]. 
We have shown that ezrin is hyperphosphorylated at T567 in CRC liver metastasis when 
compared to primary tumors [199]. Our present studies indicate that phosphorylation of ezrin at 
T567 enhances the complex formation of ezrin and PKA RII to activate PKA in favor of cell 
survival whereas dephosphorylation of ezrin at T567 facilitates the association of AKAP149 and 
PKA RII, which activates PKA and leads to induction of apoptosis. These results suggest that 
phosphorylation of ezrin at T567 acts as a signaling node, determining differential PKA 
activation accomplished by different AKAP association with PKA RII, leading to different cell 
fate. This adds to the complexity of the context-dependent AKAP-PKA interaction, which 
mediates different PKA function by directing PKA supramolecular complexes to various 
substrates, activating different downstream signaling. While ezrin-PKA association may enable 
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downstream signaling pathways that promote survival, AKAP149-PKA association likely 
activates the apoptotic pathways to induce apoptosis. Determining the dynamics of the context-
dependent interaction between PKA and different AKAPs, and the mechanisms underlying the 
activation of different downstream signaling pathways will be critical for understanding the 
function of AKAPs in regulating cell survival and metastasis of colon cancer cells.  
            XIAP and survivin are anti-apoptotic proteins important for cell survival. Independent of 
their cytoprotective function, XIAP and survivin also play important roles in tumor cell invasion 
and metastasis. It has been shown that PKA/AKAP149 signaling contributes to the disruption of 
the association of XIAP/survivin through phosphorylation of survivin at Serine 20, leading to 
proteasome-mediated degradation of XIAP and induction of apoptosis [16, 124]. This regulation 
involves protein phosphatase 2A (PP2A)-mediated dephosphorylation of Akt [16]. However, it is 
not clear how ezrin/PKA enhances expression of XIAP/survivin. In addition to regulation of its 
expression, it has been shown that, under stress, pro-apoptotic proteins, XAF1, Smac and Omi, 
interact with XIAP to inhibit its anti-apoptotic function [112]. Given the importance of XIAP and 
survivin in cancer metastasis and relative lack of knowledge of their regulation, more studies are 
needed to determine the mechanisms of regulation of their expression and function.  
            In summary, we have made novel observations that TGFβ/Smad3 and IGF1R signaling 
activate PKA through differential regulation of ezrin phosphorylation and activation, leading to 
induction of apoptosis or promotion of cell survival (Figure 8).  Our studies uncover a novel 
mechanism by which TGFβ and IGF1R signaling crosstalk to mediate apoptosis and cell survival. 
This is of significance because TGFβ and IGF1R signaling pathways are well characterized tumor 
suppressor and oncogenic pathways respectively with important roles in CRC tumorigenesis and 
metastasis. Since they both function through regulation of ezrin activation, ezrin could be used as 
a potential therapeutic target in CRC treatment. . 
4.6.    Figures 
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Figure 4.1.  Knockdown of ezrin expression activates PKA and induces apoptosis in colon 
cancer cells: A, GEO and FET colon cancer cells with stable expression of ezrin shRNA (sh#1 
and sh#3) showed a significant reduction in ezrin protein expression. Non-targeting sh RNA (NT 
sh) was used as a control. B, Ezrin KD cells showed an approximately 2-fold increase in 
apoptosis, as determined by DNA fragmentation assays. C, Ezrin KD led to downregulation of 
XIAP and survivin and an increase in cleaved caspase 7. D, Ezrin KD in GEO and FET cells 
exhibited increased PKA activation compared to NT sh cells. Forskolin (10µM)  was used as a 
positive control. E, Ezrin KD- mediated increase of p-CREB is abrogated by PKA inhibitor H89 
(15 µM). F, IP assays showed that the association of PKARII with PKACatα was decreased in 
ezrin KD cells compared with NT sh control cells. G, Production of cAMP was not increased in 























Figure 4.2.  Knockdown of ezrin expression induces apoptosis through PKA activation: A, 
Expression of PKA catalytic α subunit was knocked down in FET cells, with no change in ezrin 
phosphorylation at T567 and XIAP and survivin expression. B, PKACatα KD blocked 
endogenous as well as ezrin KD-mediated PKA activation. C&D, PKACatα KD abrogates ezrin 




























Figure 4.3.  Dephosphorylation of ezrin at T567 regulates PKA activation and apoptosis in 
GEO cells: A, Ezrin T567A downregulated XIAP and survivin expression and increased caspase 
7 cleavage. B, Ezrin T567A increased apoptosis. C&D, Ezrin T567A activated PKA with no 







































Figure 4.4.  Inhibition of Ezrin phosphorylation at T567 by NSC668394 induces apoptosis 
through PKA activation: A&B, GEO and FET colon cancer cells treated with the ezrin inhibitor 
NSC668394 (NSC) showed dose-dependent decrease in phosphorylation of ezrin at T567, 
downregulation of XIAP and survivin expression (A) and induction of apoptosis (B). C, PKA 
activity assays showed PKA activation by NSC (20 μM) treatment. PKA inhibitor H89 (15 μM) 
pretreatment abrogated endogenous and NSC-induced PKA activation. Forskolin was used as a 
positive control. D, NSC-induced PKA activation is independent of cAMP production. E, 
PKACatα KD blocked NSC-mediated XIAP and survivin downregulation. F&G, PKACatα KD 































Figure 4.5.  TGFβ inhibits ezrin phosphorylation at T567, resulting in PKA activation and 
inhibition of XIAP and survivin expression: A, TGFβ1 treatment of FET cells decreased ezrin 
phosphorylation at T567 in a time-dependent manner. B, Expression of Smad2 and Smad3 was 
knocked down in FET cells. C, Smad3KD, but not Smad2KD, prevented TGFβ1-mediated 
inhibition of ezrin phosphorylation. D, TGFβ1 treatment increased PKA activation to a much 
lesser degree in ezrin KD cells than in NT sh control cells. E, NSC attenuated TGFβ-induced 
PKA activation. F&G, Ezrin KD has no effect on TGFβRI or TGFβRII expression (F), or on 






































Figure 4.6.  Hyperphosphorylation of ezrin at T567 activates PKA and promotes survival: 
A, Transferrin and insulin (TI) treatment increased phosphorylation of ezrin at T567 and 
expression of XIAP and survivin in NT sh control cells. However, the increase was abrogated in 
ezrin KD cells. B&C, TI activated PKA (B) and increased cAMP production (C) in GEO and 
FET cells. D&E, Ectopic expression of ezrin T567 phosho-mimetic mutant (T567D) and wild 
type ezrin (WT) increased XIAP and survivin expression (D) and reduced apoptosis (E) in GEO 
Cells. F&G, Ezrin T567D mutant enhanced PKA activation (F) concomitant with increased 





























Figure 4.7.  PKA activation induced by ezrin inhibition is dependent on AKAP149 
expression: A, Pre-treatment with a pan AKAP inhibitor Ht31 (25μM) abrogated NSC-mediated 
PKA activation in FET, GEO and CBS cells. B, AKAP149 KD had no effect on expression of 
ezrin, XIAP and survivin in FET NT sh control cells but restored XIAP and survivin expression 
mediated by ezrin KD. C, AKAP149 KD abrogated ezrin KD-mediated apoptosis. D, AKAP149 
KD blocked NSC-mediated PKA activation. E, Reciprocal IP analysis with AKAP149 or PKARII 
antibodies showed increased binding of AKAP149 with PKARII in ezrin T567A cells and 
decreased binding in ezrin T567D cells. F, IP analysis with ezrin or PKARII antibodies indicated 





































Figure 4.8.  Proposed model of crosstalk between TGFβ/Smad3 and IGF1R signaling 
pathways: TGFβ/Smad3 inhibits ezrin phosphorylation at T567, leading to the association of 
PKA RII with AKAP149 to activate PKA in a cAMP-independent manner, which suppresses 
XIAP and survivin expression and induces apoptosis. With IGF1R activation, ezrin is 
hyperphosphorylated at T567, which results in association of ezrin with PKA RII and PKA 








































Figure S4.1. Ezrin inhibition leads to PKA activation in CBS cells: NSC (20μM) treatment of 
CBS cells resulted in PKA activation; PKA inhibitor H89 (15μM) pretreatment abrogated NSC- 




















































Figure S4.2: Knockdown of AKAP149 has no effect on ezrin phosphorylation and 
knockdown of ezrin does not affect AKAP149 expression: A, AKAP149 KD had no effect on 















































































5.    Discussion 
5.1.    Central theme 
In this dissertation we have identified molecules with potential role in CRC cell survival 
regulation. Cell survival is one of the critical steps in tumor invasion and metastatic colonization 
[5, 8]. Ezrin has been shown to play a role in tumorigenesis of many cancers including colon 
cancer [82, 83, 85, 86]. Using a proteomic approach, we identified ezrin as one of the molecules 
upregulated in liver metastasis compared to the primary tumor using orthotopically implanted 
mouse model. To better understand the effect of ezrin in CRC, we developed ezrin stable 
knockdown cells as well as ezrin T567 mutants. Extensive work has been done on the role of 
ezrin in many cancers but the mechanism behind its role in tumorigenesis remains elusive. 
5.2.   Current Standing 
In this dissertation a novel potential TGFβ/Smad3/IGF1R/ezrin/PKA signaling pathway was 
identified where TGFβ/Smad3 and IGF1R signaling crosstalk with each other to mediate different 
CRC cell fate through regulation of ezrin activation. 
             In chapter 2, we have demonstrated that MK-0646, a novel humanized IGF1R 
monoclonal antibody and IGF1R small molecule inhibitor OSI-906 have comparable antitumor 
effects. IGF1R signaling plays multiple roles in cancer development including aberrant cell 
survival mechanisms, proliferation, angiogenesis and metastasis [22, 27].With in vitro and in vivo 
studies, we showed for the first time in this chapter that treatment of CRC cells with MK-0646 
leads to the downregulation of XIAP and induction of cell death, demonstrating that IGF1R 
signaling controls aberrant cell survival signaling. Therefore, MK-0646 may be a potential novel 
targeted therapy against an IGF1R-dependent subset of human CRC. 
             In chapter 3, a proteomics-based technique (2D-Difference Gel Electrophoresis) coupled 
with mass spectrometry (MS) was utilized to identify proteins that may serve as potential 
therapeutic targets against metastasis. We identified increased expression of ezrin in liver 
144 
  
metastases in comparison to the primary colon tumor in orthotopic human GEO cell implants, and 
this result was validated by microarray and western blot analysis. Ezrin, a protein belonging to 
the ezrin-radixin-moesin (ERM) family, plays important roles in cell motility, invasion, tumor 
progression and metastasis [81-83, 85] and is activated through phosphorylation at T567 [79, 89, 
194]. We observed that ezrin T567 hyperphosphorylation was correlated with CRC metastasis by 
western blot and immunohistochemistry (IHC) analyses of the orthotopically implanted mouse 
primary tumors and liver metastases. This result was further validated by IHC on human CRC 
patient specimens. Moreover, inhibition of the IGF1R signaling pathway by the humanized 
monoclonal antibody MK-0646 in mouse CRC subcutaneous xenografts resulted in the inhibition 
of ezrin phosphorylation at T567, indicating that ezrin signaling is downstream of the IGF1R 
signaling pathway. SiRNA knockdown of ezrin as well as inhibition of ezrin with the ezrin 
inhibitor NSC668394 led to significant downregulation of both XIAP and survivin and induction 
of apoptosis. Therefore, using a proteomics approach, we identified ezrin as a potential biomarker 
for metastasis in CRC and showed for the first time that ezrin activation at T567 is downstream of 
the IGF1R signaling pathway and contributes to cell survival in CRC. Thus, ezrin might be a 
novel target that could be utilized for the development of effective anti-metastatic therapies 
against CRC. 
             In chapter 4, we developed a mechanistic approach to dissect the molecular mechanism 
underlying ezrin mediated CRC cell survival. Ezrin is an A-kinase anchoring protein (AKAP) that 
binds to PKA in a cAMP-dependent manner [103]. We demonstrated that inhibition of ezrin 
expression activates PKA in a cAMP-independent manner leading to induction of apoptosis and 
downregulation of XIAP and survivin. We also demonstrated that TGFβ1 treatment led to the 
dephosphorylation of ezrin T567 in scrambled cells but not in the Smad3 knockdown cells 
indicating that ezrin signaling is downstream of the TGFβ/Smad3 signaling pathway. Previously 
it has been shown that TGFβ/Smad3 signaling regulates PKA signaling in an AKAP149-
dependent manner, leading to induction of apoptosis. Here we showed that ezrin-inhibition 
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mediated PKA activation is downstream of TGFβ/Smad3 signaling and dependent on AKAP149. 
Interestingly, transferrin and insulin-mediated ezrin hyperphosphorylation at T567 has the 
opposite effect in which there is cAMP dependent PKA activation leading to CRC cell survival 
and upregulation of XIAP and survivin. These results were further confirmed with ezrin T567 
phospho-deficient (T567A) and phospho-mimetic (T567D) mutants, which demonstrated PKA 
activation by cAMP-independent and dependent mechanisms, respectively, leading to different 
CRC cell fate. Therefore, ezrin signaling demonstrated two opposing pathways in which both 
require activation of PKA and yet result in different CRC cell fates by regulating XIAP and 
survivin expression. A potential TGFβ/Smad3/IGF1R/ezrin/PKA signaling pathway was also 
identified where TGFβ/Smad3 and IGF1R signaling crosstalk with each other to mediate 
apoptosis and cell survival through regulation of ezrin activation. This crosstalk is of significance 
because TGFβ and IGF1R signaling pathways have been shown to play key roles in CRC 
tumorigenesis and metastasis, and are well characterized tumor suppressor and oncogenic 
pathways, respectively.  Therefore, ezrin might be a novel target that could be utilized for the 
development of new therapeutic strategy. Further understanding the mechanism of ezrin/cAMP-
PKA activation and its role in CRC cell survival could have potential impact for treatment of 
distant metastases in CRC. 
5.3.    Future Directions 
This dissertation study has reported that ezrin is critical for CRC cell survival through XIAP and 
survivin regulation and is upregulated in metastasis. Therefore, the next step will be the 
characterization of ezrin phospho-deficient T567A and phospho-mimetic T567D mutants in 
which endogenous activation of ezrin has been altered for the modulation of malignant properties. 
An additional goal is to provide evidence that ezrin T567 phosphorylation mediates changes in 
metastatic capability by modulating XIAP/survivin dependent cell survival function. In order to 
address this hypothesis, in vivo experiments will be performed using these mutants to determine 
146 
  
CRC metastatic colonization as well as maintenance of established metastasis. Effects of ezrin 
T567 hyperphosphorylation on XIAP/survivin complex cell survival mechanisms resulting in 
metastatic spread will also be determined in vivo in this section. Another aspect is to utilize 
IGF1R antagonists as a rationale for further pre-clinical studies in order to dissect the 
IGF1R/ezrin signaling pathway to obtain full benefit from this receptor targeted therapy as a 
single agent or in combination against CRC as well as other solid tumors dependent upon IGF1R 
signaling. 
             While aberrant cell survival and cell death mechanisms are well established, little is 
known about the specific interaction of these mechanisms and how these mechanisms compete 
each other with respect to the successful metastatic colonization. We have identified a novel 
potential crosstalk between TGFβ/Smad3 and IGF1R signaling pathway (Figure 4.8) that plays a 
differential role in CRC cell fate through regulation of ezrin/PKA activation in either a cAMP-
independent or -dependent manner, respectively, leading either to cell death or cell survival. This 
mechanism is mediated through XIAP and survivin expression. Given that survivin/XIAP 
complex formation is also known to be a critical survival factor for metastases, these data indicate 
that the balance of cAMP independent and dependent PKA signaling is a crucial determinant of 
cell fate in the process of establishing CRC distant metastases. Therefore, understanding the 
mechanism of crosstalk between TGFβ/Smad3 and IGF1R signaling pathway leading to cAMP-
independent and -dependent PKA activation may well help in the identification of novel targets as 
well as the development of new therapeutic approaches against CRC metastasis. Furthermore, 
characterization of specific molecular signatures associated with ezrin-PKA complex signaling 
will enhance our understanding of the different functions of ezrin. This may further help in the 
identification of the potential novel therapeutic targets that promote cAMP-independent PKA 




5.4.    Final Conclusions 
Overall the work in this dissertation has provided insight into potential molecular mechanisms of 
colorectal cancer (CRC) metastasis. This work has demonstrated that ezrin signaling plays a 
critical role in CRC tumorigenesis and is upregulated in CRC metastasis.  Early diagnosis and 
treatment of CRC provides avenue for the complete cure of the disease. Cell survival is one of the 
early and critical steps in cancer tumorigenesis as well as metastatic colonization, and identifying 
molecules involved in this mechanism will bring major advancements in the treatment strategy of 
CRC. Therefore, ezrin holds promise as a potential predictive or prognostic marker for treatment 
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7.1. Appendix A.  
Table S3.1. Mass spectrometry analysis of protein spot number 2. 
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